JP2023528547A - 少なくとも1つのnを含む5員ヘテロアリール誘導体、ならびにこれを有効成分として含有する精神障害の予防または治療に使用するための医薬組成物 - Google Patents
少なくとも1つのnを含む5員ヘテロアリール誘導体、ならびにこれを有効成分として含有する精神障害の予防または治療に使用するための医薬組成物 Download PDFInfo
- Publication number
- JP2023528547A JP2023528547A JP2023517643A JP2023517643A JP2023528547A JP 2023528547 A JP2023528547 A JP 2023528547A JP 2023517643 A JP2023517643 A JP 2023517643A JP 2023517643 A JP2023517643 A JP 2023517643A JP 2023528547 A JP2023528547 A JP 2023528547A
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- triazol
- indole
- benzylpiperidin
- disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000020016 psychiatric disease Diseases 0.000 title claims abstract description 33
- 239000004480 active ingredient Substances 0.000 title claims abstract description 21
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 17
- 125000006163 5-membered heteroaryl group Chemical group 0.000 title abstract description 7
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims abstract description 58
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims abstract description 51
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 claims abstract description 29
- 229960003638 dopamine Drugs 0.000 claims abstract description 29
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 claims abstract description 29
- 229960002748 norepinephrine Drugs 0.000 claims abstract description 29
- 229940076279 serotonin Drugs 0.000 claims abstract description 24
- 238000011282 treatment Methods 0.000 claims abstract description 21
- 230000002265 prevention Effects 0.000 claims abstract description 11
- 150000001875 compounds Chemical class 0.000 claims description 91
- -1 or S and A4 is NH Inorganic materials 0.000 claims description 52
- 229910052736 halogen Inorganic materials 0.000 claims description 49
- 150000002367 halogens Chemical class 0.000 claims description 49
- 150000003839 salts Chemical class 0.000 claims description 42
- 239000000203 mixture Substances 0.000 claims description 33
- 229910052739 hydrogen Inorganic materials 0.000 claims description 31
- 239000001257 hydrogen Substances 0.000 claims description 31
- 150000002431 hydrogen Chemical class 0.000 claims description 28
- 125000000217 alkyl group Chemical group 0.000 claims description 22
- 229910052760 oxygen Inorganic materials 0.000 claims description 21
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims description 18
- 208000002193 Pain Diseases 0.000 claims description 16
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 14
- 125000003545 alkoxy group Chemical group 0.000 claims description 14
- 229910052799 carbon Inorganic materials 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 230000036407 pain Effects 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 11
- 208000035475 disorder Diseases 0.000 claims description 10
- 125000004366 heterocycloalkenyl group Chemical group 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 8
- 208000019906 panic disease Diseases 0.000 claims description 8
- 208000019022 Mood disease Diseases 0.000 claims description 7
- 230000036541 health Effects 0.000 claims description 7
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
- 208000004296 neuralgia Diseases 0.000 claims description 7
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 7
- 208000030814 Eating disease Diseases 0.000 claims description 6
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 6
- 235000014632 disordered eating Nutrition 0.000 claims description 6
- 208000021722 neuropathic pain Diseases 0.000 claims description 6
- 208000011117 substance-related disease Diseases 0.000 claims description 6
- 208000011580 syndromic disease Diseases 0.000 claims description 6
- 239000003174 triple reuptake inhibitor Substances 0.000 claims description 6
- 208000019901 Anxiety disease Diseases 0.000 claims description 5
- 206010012289 Dementia Diseases 0.000 claims description 5
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 5
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims description 5
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims description 5
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 5
- 208000024891 symptom Diseases 0.000 claims description 5
- PCWCPTSKDSYWBJ-UHFFFAOYSA-N 2-[5-[(4-benzylpiperazin-1-yl)methyl]-1H-1,2,4-triazol-3-yl]-5-fluoro-1H-indole Chemical compound FC1=CC=C2NC(C3=NN=C(CN4CCN(CC5=CC=CC=C5)CC4)N3)=CC2=C1 PCWCPTSKDSYWBJ-UHFFFAOYSA-N 0.000 claims description 4
- GFIOUUKKLSNOJE-UHFFFAOYSA-N 2-[5-[(4-benzylpiperidin-1-yl)methyl]-1H-1,2,4-triazol-3-yl]-1H-indole Chemical compound C(C1CCN(CC2=NN=C(C3=CC4=CC=CC=C4N3)N2)CC1)C1=CC=CC=C1 GFIOUUKKLSNOJE-UHFFFAOYSA-N 0.000 claims description 4
- UKBZLPJPSAGJEV-UHFFFAOYSA-N 2-[5-[(4-benzylpiperidin-1-yl)methyl]-1H-1,2,4-triazol-3-yl]-1H-indole-5-carboxylic acid Chemical compound OC(C1=CC=C2NC(C3=NN=C(CN4CCC(CC5=CC=CC=C5)CC4)N3)=CC2=C1)=O UKBZLPJPSAGJEV-UHFFFAOYSA-N 0.000 claims description 4
- XELMWECAVFTNMJ-UHFFFAOYSA-N 3-[5-[(4-benzylpiperidin-1-yl)methyl]-1H-1,2,4-triazol-3-yl]-6-methoxy-1H-indole Chemical compound COC1=CC=C(C(C2=NN=C(CN3CCC(CC4=CC=CC=C4)CC3)N2)=CN2)C2=C1 XELMWECAVFTNMJ-UHFFFAOYSA-N 0.000 claims description 4
- UHNDJDVJPHMMLX-UHFFFAOYSA-N 4-[5-[(4-benzylpiperidin-1-yl)methyl]-1H-1,2,4-triazol-3-yl]benzonitrile Chemical compound N#CC(C=C1)=CC=C1C1=NN=C(CN2CCC(CC3=CC=CC=C3)CC2)N1 UHNDJDVJPHMMLX-UHFFFAOYSA-N 0.000 claims description 4
- 208000007848 Alcoholism Diseases 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 4
- 208000020925 Bipolar disease Diseases 0.000 claims description 4
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 4
- 206010041250 Social phobia Diseases 0.000 claims description 4
- 208000008548 Tension-Type Headache Diseases 0.000 claims description 4
- 201000007930 alcohol dependence Diseases 0.000 claims description 4
- 125000002947 alkylene group Chemical group 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 208000019116 sleep disease Diseases 0.000 claims description 4
- KOGCXNCAEIRVNW-UHFFFAOYSA-N (4-benzylpiperidin-1-yl)-[3-(4-methoxyphenyl)-1H-1,2,4-triazol-5-yl]methanone Chemical compound COC(C=C1)=CC=C1C1=NN=C(C(N2CCC(CC3=CC=CC=C3)CC2)=O)N1 KOGCXNCAEIRVNW-UHFFFAOYSA-N 0.000 claims description 3
- XCXHHNXEEKWMAW-UHFFFAOYSA-N (4-benzylpiperidin-1-yl)-[3-(5-fluoro-1H-indol-2-yl)-1H-1,2,4-triazol-5-yl]methanone Chemical compound O=C(C1=NN=C(C2=CC3=CC(F)=CC=C3N2)N1)N1CCC(CC2=CC=CC=C2)CC1 XCXHHNXEEKWMAW-UHFFFAOYSA-N 0.000 claims description 3
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 claims description 3
- JMFLXRZBNTXEPG-UHFFFAOYSA-N 2-[(4-benzylpiperidin-1-yl)methyl]-5-(1H-indol-2-yl)-1,3,4-oxadiazole Chemical compound C(C1CCN(CC2=NN=C(C3=CC4=CC=CC=C4N3)O2)CC1)C1=CC=CC=C1 JMFLXRZBNTXEPG-UHFFFAOYSA-N 0.000 claims description 3
- LMHXYOGVYYKXEJ-UHFFFAOYSA-N 2-[5-[(4-benzylpiperidin-1-yl)methyl]-1H-1,2,4-triazol-3-yl]-1H-indol-5-ol Chemical compound OC1=CC=C2NC(C3=NN=C(CN4CCC(CC5=CC=CC=C5)CC4)N3)=CC2=C1 LMHXYOGVYYKXEJ-UHFFFAOYSA-N 0.000 claims description 3
- BTQFQRRYBWCODZ-UHFFFAOYSA-N 2-[5-[(4-benzylpiperidin-1-yl)methyl]-1H-1,2,4-triazol-3-yl]-1H-indole-5,6-diol Chemical compound OC(C=C(C=C(C1=NN=C(CN2CCC(CC3=CC=CC=C3)CC2)N1)N1)C1=C1)=C1O BTQFQRRYBWCODZ-UHFFFAOYSA-N 0.000 claims description 3
- KDYOIEUQOLRLNB-UHFFFAOYSA-N 2-[5-[(4-benzylpiperidin-1-yl)methyl]-1H-1,2,4-triazol-3-yl]-1H-indole-5-carboxamide Chemical compound NC(C1=CC=C2NC(C3=NN=C(CN4CCC(CC5=CC=CC=C5)CC4)N3)=CC2=C1)=O KDYOIEUQOLRLNB-UHFFFAOYSA-N 0.000 claims description 3
- GGPJDQGDHBBSOT-UHFFFAOYSA-N 2-[5-[(4-benzylpiperidin-1-yl)methyl]-1H-1,2,4-triazol-3-yl]-5,6-dimethoxy-1H-indole Chemical compound COC(C=C(C=C(C1=NN=C(CN2CCC(CC3=CC=CC=C3)CC2)N1)N1)C1=C1)=C1OC GGPJDQGDHBBSOT-UHFFFAOYSA-N 0.000 claims description 3
- KHWFZEHZVOAFHV-UHFFFAOYSA-N 2-[5-[(4-benzylpiperidin-1-yl)methyl]-1H-1,2,4-triazol-3-yl]-5-methoxy-1H-indole Chemical compound COC1=CC=C2NC(C3=NN=C(CN4CCC(CC5=CC=CC=C5)CC4)N3)=CC2=C1 KHWFZEHZVOAFHV-UHFFFAOYSA-N 0.000 claims description 3
- XKFBUBBGUQTGBH-UHFFFAOYSA-N 2-[5-[(4-benzylpiperidin-1-yl)methyl]-1H-1,2,4-triazol-3-yl]-6-butoxy-1H-indole Chemical compound CCCCOC1=CC=C(C=C(C2=NN=C(CN3CCC(CC4=CC=CC=C4)CC3)N2)N2)C2=C1 XKFBUBBGUQTGBH-UHFFFAOYSA-N 0.000 claims description 3
- CYEZHHPSYDCUDG-UHFFFAOYSA-N 2-[[4-[(3,4-dichlorophenyl)methyl]piperidin-1-yl]methyl]-5-(1H-indol-2-yl)-1,3,4-oxadiazole Chemical compound ClC(C=CC(CC1CCN(CC2=NN=C(C3=CC4=CC=CC=C4N3)O2)CC1)=C1)=C1Cl CYEZHHPSYDCUDG-UHFFFAOYSA-N 0.000 claims description 3
- UKSUBXFVLLMVSH-UHFFFAOYSA-N 3-[5-[(4-benzylpiperidin-1-yl)methyl]-1H-1,2,4-triazol-3-yl]-1H-indol-5-amine Chemical compound NC(C=C12)=CC=C1NC=C2C1=NN=C(CN2CCC(CC3=CC=CC=C3)CC2)N1 UKSUBXFVLLMVSH-UHFFFAOYSA-N 0.000 claims description 3
- JJGOZJNIZDTPST-UHFFFAOYSA-N 3-[5-[(4-benzylpiperidin-1-yl)methyl]-1H-1,2,4-triazol-3-yl]-5-methoxy-1H-indole Chemical compound COC(C=C12)=CC=C1NC=C2C1=NN=C(CN2CCC(CC3=CC=CC=C3)CC2)N1 JJGOZJNIZDTPST-UHFFFAOYSA-N 0.000 claims description 3
- LPMHTNFISZAWDD-UHFFFAOYSA-N 3-[5-[[4-[(3,4-dichlorophenyl)methyl]piperidin-1-yl]methyl]-1H-1,2,4-triazol-3-yl]-6-methoxy-1H-indole Chemical compound COC1=CC=C(C(C2=NN=C(CN3CCC(CC(C=C4)=CC(Cl)=C4Cl)CC3)N2)=CN2)C2=C1 LPMHTNFISZAWDD-UHFFFAOYSA-N 0.000 claims description 3
- XHKSJZMENDYHJH-UHFFFAOYSA-N 4-[5-[(4-benzylpiperidin-1-yl)methyl]-1H-1,2,4-triazol-3-yl]-N-[2-(dimethylamino)ethyl]benzamide Chemical compound CN(C)CCNC(C(C=C1)=CC=C1C1=NN=C(CN2CCC(CC3=CC=CC=C3)CC2)N1)=O XHKSJZMENDYHJH-UHFFFAOYSA-N 0.000 claims description 3
- VGYNKRVZWVDZCE-UHFFFAOYSA-N 4-benzyl-1-[(3-phenyl-1H-1,2,4-triazol-5-yl)methyl]piperidine Chemical compound C(C1CCN(CC2=NN=C(C3=CC=CC=C3)N2)CC1)C1=CC=CC=C1 VGYNKRVZWVDZCE-UHFFFAOYSA-N 0.000 claims description 3
- FMDQYKVZHLKQAL-UHFFFAOYSA-N 4-benzyl-1-[[3-(4-methoxyphenyl)-1H-1,2,4-triazol-5-yl]methyl]piperidine Chemical compound COC(C=C1)=CC=C1C1=NN=C(CN2CCC(CC3=CC=CC=C3)CC2)N1 FMDQYKVZHLKQAL-UHFFFAOYSA-N 0.000 claims description 3
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 3
- 208000026331 Disruptive, Impulse Control, and Conduct disease Diseases 0.000 claims description 3
- 208000010228 Erectile Dysfunction Diseases 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 206010021639 Incontinence Diseases 0.000 claims description 3
- NISIDBBBKFVXOC-UHFFFAOYSA-N N-[2-[5-[(4-benzylpiperidin-1-yl)methyl]-1H-1,2,4-triazol-3-yl]-1H-indol-5-yl]acetamide Chemical compound CC(NC1=CC=C2NC(C3=NN=C(CN4CCC(CC5=CC=CC=C5)CC4)N3)=CC2=C1)=O NISIDBBBKFVXOC-UHFFFAOYSA-N 0.000 claims description 3
- 208000013200 Stress disease Diseases 0.000 claims description 3
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims description 3
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 3
- 230000001684 chronic effect Effects 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 206010013663 drug dependence Diseases 0.000 claims description 3
- 235000013376 functional food Nutrition 0.000 claims description 3
- 201000001881 impotence Diseases 0.000 claims description 3
- 206010027175 memory impairment Diseases 0.000 claims description 3
- ALSWFKMCQNVFQK-UHFFFAOYSA-N methyl 2-[5-[(4-benzylpiperidin-1-yl)methyl]-1H-1,2,4-triazol-3-yl]-1H-indole-5-carboxylate Chemical compound COC(C1=CC=C2NC(C3=NN=C(CN4CCC(CC5=CC=CC=C5)CC4)N3)=CC2=C1)=O ALSWFKMCQNVFQK-UHFFFAOYSA-N 0.000 claims description 3
- MJUGTBYWXLPPJJ-UHFFFAOYSA-N methyl 2-amino-4-[5-[(4-benzylpiperidin-1-yl)methyl]-1H-1,2,4-triazol-3-yl]benzoate Chemical compound COC(C(C=CC(C1=NN=C(CN2CCC(CC3=CC=CC=C3)CC2)N1)=C1)=C1N)=O MJUGTBYWXLPPJJ-UHFFFAOYSA-N 0.000 claims description 3
- 201000001119 neuropathy Diseases 0.000 claims description 3
- 230000007823 neuropathy Effects 0.000 claims description 3
- 230000001575 pathological effect Effects 0.000 claims description 3
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 3
- 208000028173 post-traumatic stress disease Diseases 0.000 claims description 3
- 206010036596 premature ejaculation Diseases 0.000 claims description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 3
- FYAPXOBMBILLMF-UHFFFAOYSA-N 1-[[3-(1,3-benzodioxol-5-yl)-1H-1,2,4-triazol-5-yl]methyl]-4-benzylpiperidine Chemical compound C(C1CCN(CC2=NN=C(C(C=C3)=CC4=C3OCO4)N2)CC1)C1=CC=CC=C1 FYAPXOBMBILLMF-UHFFFAOYSA-N 0.000 claims description 2
- NDIDIKBFABYTQV-UHFFFAOYSA-N 1-[[3-(1-benzofuran-2-yl)-1H-1,2,4-triazol-5-yl]methyl]-4-benzylpiperidine Chemical compound C(C1CCN(CC2=NN=C(C3=CC(C=CC=C4)=C4O3)N2)CC1)C1=CC=CC=C1 NDIDIKBFABYTQV-UHFFFAOYSA-N 0.000 claims description 2
- FWTBPHYEZBXBSS-UHFFFAOYSA-N 1-[[3-(1-benzothiophen-2-yl)-1H-1,2,4-triazol-5-yl]methyl]-4-benzylpiperidine Chemical compound C(C1CCN(CC2=NN=C(C3=CC(C=CC=C4)=C4S3)N2)CC1)C1=CC=CC=C1 FWTBPHYEZBXBSS-UHFFFAOYSA-N 0.000 claims description 2
- RABHCFBVFFSZPW-UHFFFAOYSA-N 2-[5-[(4-benzylpiperazin-1-yl)methyl]-1H-1,2,4-triazol-3-yl]-1H-indole Chemical compound C(C1=NN=C(C2=CC3=CC=CC=C3N2)N1)N1CCN(CC2=CC=CC=C2)CC1 RABHCFBVFFSZPW-UHFFFAOYSA-N 0.000 claims description 2
- UATWCKSNMMIUCQ-UHFFFAOYSA-N 2-[5-[(4-benzylpiperazin-1-yl)methyl]-1H-1,2,4-triazol-3-yl]-5-chloro-1H-indole Chemical compound ClC1=CC=C2NC(C3=NN=C(CN4CCN(CC5=CC=CC=C5)CC4)N3)=CC2=C1 UATWCKSNMMIUCQ-UHFFFAOYSA-N 0.000 claims description 2
- UQZJCFAQRXTXCC-UHFFFAOYSA-N 2-[5-[(4-benzylpiperidin-1-yl)methyl]-1H-1,2,4-triazol-3-yl]-1H-indole-5-carbonitrile Chemical compound N#CC1=CC=C2NC(C3=NN=C(CN4CCC(CC5=CC=CC=C5)CC4)N3)=CC2=C1 UQZJCFAQRXTXCC-UHFFFAOYSA-N 0.000 claims description 2
- PUZFRFWCTJTTAH-UHFFFAOYSA-N 2-[5-[(4-benzylpiperidin-1-yl)methyl]-1H-1,2,4-triazol-3-yl]-3-methyl-1H-indole Chemical compound CC1=C(C2=NN=C(CN3CCC(CC4=CC=CC=C4)CC3)N2)NC2=CC=CC=C12 PUZFRFWCTJTTAH-UHFFFAOYSA-N 0.000 claims description 2
- WRVIIQLVAMNXIK-UHFFFAOYSA-N 2-[5-[(4-benzylpiperidin-1-yl)methyl]-1H-1,2,4-triazol-3-yl]-4,6-dichloro-1H-indole Chemical compound ClC1=CC(Cl)=C(C=C(C2=NN=C(CN3CCC(CC4=CC=CC=C4)CC3)N2)N2)C2=C1 WRVIIQLVAMNXIK-UHFFFAOYSA-N 0.000 claims description 2
- OBBBRKHLEOUHKE-UHFFFAOYSA-N 2-[5-[(4-benzylpiperidin-1-yl)methyl]-1H-1,2,4-triazol-3-yl]-4-chloro-1H-indole Chemical compound ClC1=C(C=C(C2=NN=C(CN3CCC(CC4=CC=CC=C4)CC3)N2)N2)C2=CC=C1 OBBBRKHLEOUHKE-UHFFFAOYSA-N 0.000 claims description 2
- HEJHFYRSUGCOML-UHFFFAOYSA-N 2-[5-[(4-benzylpiperidin-1-yl)methyl]-1H-1,2,4-triazol-3-yl]-5,6-dichloro-1H-indole Chemical compound ClC(C=C(C=C(C1=NN=C(CN2CCC(CC3=CC=CC=C3)CC2)N1)N1)C1=C1)=C1Cl HEJHFYRSUGCOML-UHFFFAOYSA-N 0.000 claims description 2
- VJYXJHZPGLOAKK-UHFFFAOYSA-N 2-[5-[(4-benzylpiperidin-1-yl)methyl]-1H-1,2,4-triazol-3-yl]-5-(trifluoromethyl)-1H-indole Chemical compound FC(C1=CC=C2NC(C3=NN=C(CN4CCC(CC5=CC=CC=C5)CC4)N3)=CC2=C1)(F)F VJYXJHZPGLOAKK-UHFFFAOYSA-N 0.000 claims description 2
- LXOFKWLKWLCILV-UHFFFAOYSA-N 2-[5-[(4-benzylpiperidin-1-yl)methyl]-1H-1,2,4-triazol-3-yl]-5-chloro-1H-indole Chemical compound ClC1=CC=C2NC(C3=NN=C(CN4CCC(CC5=CC=CC=C5)CC4)N3)=CC2=C1 LXOFKWLKWLCILV-UHFFFAOYSA-N 0.000 claims description 2
- AZPWKCWYCHKTRO-UHFFFAOYSA-N 2-[5-[(4-benzylpiperidin-1-yl)methyl]-1H-1,2,4-triazol-3-yl]-5-fluoro-1H-indole Chemical compound FC1=CC=C2NC(C3=NN=C(CN4CCC(CC5=CC=CC=C5)CC4)N3)=CC2=C1 AZPWKCWYCHKTRO-UHFFFAOYSA-N 0.000 claims description 2
- CZMVRTAQQQZZIU-UHFFFAOYSA-N 2-[5-[(4-benzylpiperidin-1-yl)methyl]-1H-1,2,4-triazol-3-yl]-5-methyl-1H-indole Chemical compound CC1=CC=C2NC(C3=NN=C(CN4CCC(CC5=CC=CC=C5)CC4)N3)=CC2=C1 CZMVRTAQQQZZIU-UHFFFAOYSA-N 0.000 claims description 2
- LBXSXSUCJZAUCC-UHFFFAOYSA-N 2-[5-[(4-benzylpiperidin-1-yl)methyl]-1H-1,2,4-triazol-3-yl]-6-fluoro-1H-indole Chemical compound FC1=CC=C(C=C(C2=NN=C(CN3CCC(CC4=CC=CC=C4)CC3)N2)N2)C2=C1 LBXSXSUCJZAUCC-UHFFFAOYSA-N 0.000 claims description 2
- YLDPZVJGMZDYEW-UHFFFAOYSA-N 2-[5-[(4-benzylpiperidin-1-yl)methyl]-1H-1,2,4-triazol-3-yl]-6-methoxy-1H-indole Chemical compound COC1=CC=C(C=C(C2=NN=C(CN3CCC(CC4=CC=CC=C4)CC3)N2)N2)C2=C1 YLDPZVJGMZDYEW-UHFFFAOYSA-N 0.000 claims description 2
- JTIONLAGIRLQGP-UHFFFAOYSA-N 2-[5-[(4-benzylpiperidin-1-yl)methyl]-1H-1,2,4-triazol-3-yl]-7-methoxy-1H-indole Chemical compound COC1=C2NC(C3=NN=C(CN4CCC(CC5=CC=CC=C5)CC4)N3)=CC2=CC=C1 JTIONLAGIRLQGP-UHFFFAOYSA-N 0.000 claims description 2
- PQWWDPBPDCKSPD-UHFFFAOYSA-N 2-[5-[(4-phenylpiperidin-1-yl)methyl]-1H-1,2,4-triazol-3-yl]-1H-indole Chemical compound C(C1=NN=C(C2=CC3=CC=CC=C3N2)N1)N(CC1)CCC1C1=CC=CC=C1 PQWWDPBPDCKSPD-UHFFFAOYSA-N 0.000 claims description 2
- PTZHRAKUKFUXCY-UHFFFAOYSA-N 2-[5-[[4-[(3,4-dichlorophenyl)methyl]piperidin-1-yl]methyl]-1H-1,2,4-triazol-3-yl]-1H-indole Chemical compound ClC(C=CC(CC1CCN(CC2=NN=C(C3=CC4=CC=CC=C4N3)N2)CC1)=C1)=C1Cl PTZHRAKUKFUXCY-UHFFFAOYSA-N 0.000 claims description 2
- RFSVMHQLOQWKGF-UHFFFAOYSA-N 2-[5-[[4-[(3,4-dichlorophenyl)methyl]piperidin-1-yl]methyl]-1H-1,2,4-triazol-3-yl]-5-fluoro-1H-indole Chemical compound FC1=CC=C2NC(C3=NN=C(CN4CCC(CC(C=C5)=CC(Cl)=C5Cl)CC4)N3)=CC2=C1 RFSVMHQLOQWKGF-UHFFFAOYSA-N 0.000 claims description 2
- YQBAOEAOUOECLX-UHFFFAOYSA-N 2-[5-[[4-[(3,4-dichlorophenyl)methyl]piperidin-1-yl]methyl]-1H-1,2,4-triazol-3-yl]-5-methyl-1H-indole Chemical compound CC1=CC=C2NC(C3=NN=C(CN4CCC(CC(C=C5)=CC(Cl)=C5Cl)CC4)N3)=CC2=C1 YQBAOEAOUOECLX-UHFFFAOYSA-N 0.000 claims description 2
- PVTGCPIMEWRYMS-UHFFFAOYSA-N 2-[5-[[4-[(3-chlorophenyl)methyl]piperidin-1-yl]methyl]-1H-1,2,4-triazol-3-yl]-1H-indole Chemical compound ClC1=CC=CC(CC2CCN(CC3=NN=C(C4=CC5=CC=CC=C5N4)N3)CC2)=C1 PVTGCPIMEWRYMS-UHFFFAOYSA-N 0.000 claims description 2
- GGFNCFXZGBGGEO-UHFFFAOYSA-N 2-[5-[[4-[(4-chlorophenyl)methyl]piperidin-1-yl]methyl]-1H-1,2,4-triazol-3-yl]-1H-indole Chemical compound ClC1=CC=C(CC2CCN(CC3=NN=C(C4=CC5=CC=CC=C5N4)N3)CC2)C=C1 GGFNCFXZGBGGEO-UHFFFAOYSA-N 0.000 claims description 2
- NUYFMRXAOCWSNL-UHFFFAOYSA-N 2-[5-[[4-[(4-methoxyphenyl)methyl]piperidin-1-yl]methyl]-1H-1,2,4-triazol-3-yl]-1H-indole Chemical compound COC1=CC=C(CC2CCN(CC3=NN=C(C4=CC5=CC=CC=C5N4)N3)CC2)C=C1 NUYFMRXAOCWSNL-UHFFFAOYSA-N 0.000 claims description 2
- ZNHIHZKGISFRNB-UHFFFAOYSA-N 3-[5-[(4-benzylpiperidin-1-yl)methyl]-1H-1,2,4-triazol-3-yl]-1H-indole Chemical compound C(C1CCN(CC2=NN=C(C3=CNC4=CC=CC=C34)N2)CC1)C1=CC=CC=C1 ZNHIHZKGISFRNB-UHFFFAOYSA-N 0.000 claims description 2
- WCFDTUDEPUCPQV-UHFFFAOYSA-N 3-[5-[(4-benzylpiperidin-1-yl)methyl]-1H-1,2,4-triazol-3-yl]-5-chloro-1H-indole Chemical compound ClC(C=C12)=CC=C1NC=C2C1=NN=C(CN2CCC(CC3=CC=CC=C3)CC2)N1 WCFDTUDEPUCPQV-UHFFFAOYSA-N 0.000 claims description 2
- ZUNFPYIACFFVEQ-UHFFFAOYSA-N 3-[5-[(4-benzylpiperidin-1-yl)methyl]-1H-1,2,4-triazol-3-yl]-5-methyl-1H-indole Chemical compound CC(C=C12)=CC=C1NC=C2C1=NN=C(CN2CCC(CC3=CC=CC=C3)CC2)N1 ZUNFPYIACFFVEQ-UHFFFAOYSA-N 0.000 claims description 2
- NHRNJNFWWYEQOT-UHFFFAOYSA-N 3-[5-[(4-benzylpiperidin-1-yl)methyl]-1H-1,2,4-triazol-3-yl]-6-fluoro-1H-indole Chemical compound FC1=CC=C(C(C2=NN=C(CN3CCC(CC4=CC=CC=C4)CC3)N2)=CN2)C2=C1 NHRNJNFWWYEQOT-UHFFFAOYSA-N 0.000 claims description 2
- FCYZNSIVHQBPTC-UHFFFAOYSA-N 3-[5-[(4-benzylpiperidin-1-yl)methyl]-1H-1,2,4-triazol-3-yl]-6-methyl-1H-indole Chemical compound CC1=CC=C(C(C2=NN=C(CN3CCC(CC4=CC=CC=C4)CC3)N2)=CN2)C2=C1 FCYZNSIVHQBPTC-UHFFFAOYSA-N 0.000 claims description 2
- MHMRUGJROCZLGM-UHFFFAOYSA-N 3-[5-[(4-benzylpiperidin-1-yl)methyl]-1H-1,2,4-triazol-3-yl]-7-chloro-1H-indole Chemical compound ClC(C=CC=C12)=C1NC=C2C1=NN=C(CN2CCC(CC3=CC=CC=C3)CC2)N1 MHMRUGJROCZLGM-UHFFFAOYSA-N 0.000 claims description 2
- DBSRBKSQUDSFDJ-UHFFFAOYSA-N 3-[5-[(4-benzylpiperidin-1-yl)methyl]-1H-1,2,4-triazol-3-yl]-7-methoxy-1H-indole Chemical compound COC(C=CC=C12)=C1NC=C2C1=NN=C(CN2CCC(CC3=CC=CC=C3)CC2)N1 DBSRBKSQUDSFDJ-UHFFFAOYSA-N 0.000 claims description 2
- KPZLVYLMJWQOQP-UHFFFAOYSA-N 3-[5-[[4-[(3,4-dichlorophenyl)methyl]piperidin-1-yl]methyl]-1H-1,2,4-triazol-3-yl]-5-methoxy-1H-indole Chemical compound COC(C=C12)=CC=C1NC=C2C1=NN=C(CN2CCC(CC(C=C3)=CC(Cl)=C3Cl)CC2)N1 KPZLVYLMJWQOQP-UHFFFAOYSA-N 0.000 claims description 2
- DKIOXBPOQDQGSE-UHFFFAOYSA-N 3-[5-[[4-[(3,4-dichlorophenyl)methyl]piperidin-1-yl]methyl]-1H-1,2,4-triazol-3-yl]-7-methoxy-1H-indole Chemical compound COC(C=CC=C12)=C1NC=C2C1=NN=C(CN2CCC(CC(C=C3)=CC(Cl)=C3Cl)CC2)N1 DKIOXBPOQDQGSE-UHFFFAOYSA-N 0.000 claims description 2
- DCSBPKXOKMOENM-UHFFFAOYSA-N 4-[(3,4-dichlorophenyl)methyl]-1-[[3-[4-(trifluoromethoxy)phenyl]-1H-1,2,4-triazol-5-yl]methyl]piperidine Chemical compound FC(OC(C=C1)=CC=C1C1=NN=C(CN2CCC(CC(C=C3)=CC(Cl)=C3Cl)CC2)N1)(F)F DCSBPKXOKMOENM-UHFFFAOYSA-N 0.000 claims description 2
- BCAUBJSBEQEVCG-UHFFFAOYSA-N 4-[(3,4-dichlorophenyl)methyl]-1-[[3-[4-(trifluoromethyl)phenyl]-1H-1,2,4-triazol-5-yl]methyl]piperidine Chemical compound FC(C(C=C1)=CC=C1C1=NN=C(CN2CCC(CC(C=C3)=CC(Cl)=C3Cl)CC2)N1)(F)F BCAUBJSBEQEVCG-UHFFFAOYSA-N 0.000 claims description 2
- PUSVIFCNOJRQTI-UHFFFAOYSA-N 4-benzyl-1-[(3-naphthalen-2-yl-1H-1,2,4-triazol-5-yl)methyl]piperidine Chemical compound C(C1CCN(CC2=NN=C(C3=CC4=CC=CC=C4C=C3)N2)CC1)C1=CC=CC=C1 PUSVIFCNOJRQTI-UHFFFAOYSA-N 0.000 claims description 2
- JIQZDDZLXHYAHW-UHFFFAOYSA-N 4-benzyl-1-[[3-(3,4-dimethoxyphenyl)-1H-1,2,4-triazol-5-yl]methyl]piperidine Chemical compound COC(C=CC(C1=NN=C(CN2CCC(CC3=CC=CC=C3)CC2)N1)=C1)=C1OC JIQZDDZLXHYAHW-UHFFFAOYSA-N 0.000 claims description 2
- UHJNSVPGNNWPFU-UHFFFAOYSA-N 4-benzyl-1-[[3-(4-fluorophenyl)-1H-1,2,4-triazol-5-yl]methyl]piperidine Chemical compound FC(C=C1)=CC=C1C1=NN=C(CN2CCC(CC3=CC=CC=C3)CC2)N1 UHJNSVPGNNWPFU-UHFFFAOYSA-N 0.000 claims description 2
- ZKFBBUKIULKGSV-UHFFFAOYSA-N 4-benzyl-1-[[3-(4-phenoxyphenyl)-1H-1,2,4-triazol-5-yl]methyl]piperidine Chemical compound C(C1CCN(CC2=NN=C(C(C=C3)=CC=C3OC3=CC=CC=C3)N2)CC1)C1=CC=CC=C1 ZKFBBUKIULKGSV-UHFFFAOYSA-N 0.000 claims description 2
- QNBRGXOPQYJUIG-UHFFFAOYSA-N 4-benzyl-1-[[3-[3-(trifluoromethoxy)phenyl]-1H-1,2,4-triazol-5-yl]methyl]piperidine Chemical compound FC(OC1=CC=CC(C2=NN=C(CN3CCC(CC4=CC=CC=C4)CC3)N2)=C1)(F)F QNBRGXOPQYJUIG-UHFFFAOYSA-N 0.000 claims description 2
- GGMBCXIWJUGVRK-UHFFFAOYSA-N 4-benzyl-1-[[3-[3-(trifluoromethyl)phenyl]-1H-1,2,4-triazol-5-yl]methyl]piperidine Chemical compound FC(C1=CC=CC(C2=NN=C(CN3CCC(CC4=CC=CC=C4)CC3)N2)=C1)(F)F GGMBCXIWJUGVRK-UHFFFAOYSA-N 0.000 claims description 2
- TZVJANRDSMFGPJ-UHFFFAOYSA-N 4-benzyl-1-[[3-[4-(trifluoromethoxy)phenyl]-1H-1,2,4-triazol-5-yl]methyl]piperidine Chemical compound FC(OC(C=C1)=CC=C1C1=NN=C(CN2CCC(CC3=CC=CC=C3)CC2)N1)(F)F TZVJANRDSMFGPJ-UHFFFAOYSA-N 0.000 claims description 2
- LJNRAQHUBQEUJM-UHFFFAOYSA-N 4-benzyl-1-[[3-[4-(trifluoromethyl)phenyl]-1H-1,2,4-triazol-5-yl]methyl]piperidine Chemical compound FC(C(C=C1)=CC=C1C1=NN=C(CN2CCC(CC3=CC=CC=C3)CC2)N1)(F)F LJNRAQHUBQEUJM-UHFFFAOYSA-N 0.000 claims description 2
- PGUMRLBMJQZXOW-UHFFFAOYSA-N 5-fluoro-2-[5-[[4-(1H-indol-3-yl)piperidin-1-yl]methyl]-1H-1,2,4-triazol-3-yl]-1H-indole Chemical compound FC1=CC=C2NC(C3=NN=C(CN(CC4)CCC4C4=CNC5=CC=CC=C45)N3)=CC2=C1 PGUMRLBMJQZXOW-UHFFFAOYSA-N 0.000 claims description 2
- JZJFYVBEKJGUSQ-UHFFFAOYSA-N 6-[5-[(4-benzylpiperidin-1-yl)methyl]-1H-1,2,4-triazol-3-yl]-1H-indole Chemical compound C(C1CCN(CC2=NN=C(C3=CC=C(C=CN4)C4=C3)N2)CC1)C1=CC=CC=C1 JZJFYVBEKJGUSQ-UHFFFAOYSA-N 0.000 claims description 2
- KRCHYRXNOUAXHZ-UHFFFAOYSA-N 6-[5-[(4-benzylpiperidin-1-yl)methyl]-1H-1,2,4-triazol-3-yl]naphthalen-2-ol Chemical compound OC(C=CC1=C2)=CC1=CC=C2C1=NN=C(CN2CCC(CC3=CC=CC=C3)CC2)N1 KRCHYRXNOUAXHZ-UHFFFAOYSA-N 0.000 claims description 2
- 208000030507 AIDS Diseases 0.000 claims description 2
- 208000008811 Agoraphobia Diseases 0.000 claims description 2
- 208000000044 Amnesia Diseases 0.000 claims description 2
- 208000036640 Asperger disease Diseases 0.000 claims description 2
- 201000006062 Asperger syndrome Diseases 0.000 claims description 2
- 206010003805 Autism Diseases 0.000 claims description 2
- 208000020706 Autistic disease Diseases 0.000 claims description 2
- 208000008035 Back Pain Diseases 0.000 claims description 2
- 206010006550 Bulimia nervosa Diseases 0.000 claims description 2
- VVYRYWNNLSMLHF-UHFFFAOYSA-N C(C1CCN(CC2=NN=C(C3=CC(C=C4OCOC4=C4)=C4N3)N2)CC1)C1=CC=CC=C1 Chemical compound C(C1CCN(CC2=NN=C(C3=CC(C=C4OCOC4=C4)=C4N3)N2)CC1)C1=CC=CC=C1 VVYRYWNNLSMLHF-UHFFFAOYSA-N 0.000 claims description 2
- 206010058019 Cancer Pain Diseases 0.000 claims description 2
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims description 2
- 208000000094 Chronic Pain Diseases 0.000 claims description 2
- 208000022497 Cocaine-Related disease Diseases 0.000 claims description 2
- 208000019736 Cranial nerve disease Diseases 0.000 claims description 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 2
- 201000010374 Down Syndrome Diseases 0.000 claims description 2
- 208000026097 Factitious disease Diseases 0.000 claims description 2
- 208000011688 Generalised anxiety disease Diseases 0.000 claims description 2
- 206010065390 Inflammatory pain Diseases 0.000 claims description 2
- 208000008930 Low Back Pain Diseases 0.000 claims description 2
- 208000019695 Migraine disease Diseases 0.000 claims description 2
- 208000016285 Movement disease Diseases 0.000 claims description 2
- 206010028403 Mutism Diseases 0.000 claims description 2
- 208000000112 Myalgia Diseases 0.000 claims description 2
- QLMSWNUNNJKRLI-UHFFFAOYSA-N N-[4-[5-[(4-benzylpiperidin-1-yl)methyl]-1H-1,2,4-triazol-3-yl]phenyl]acetamide Chemical compound CC(NC(C=C1)=CC=C1C1=NN=C(CN2CCC(CC3=CC=CC=C3)CC2)N1)=O QLMSWNUNNJKRLI-UHFFFAOYSA-N 0.000 claims description 2
- 208000008705 Nocturnal Myoclonus Syndrome Diseases 0.000 claims description 2
- 208000008589 Obesity Diseases 0.000 claims description 2
- 206010033664 Panic attack Diseases 0.000 claims description 2
- 206010052794 Panic disorder with agoraphobia Diseases 0.000 claims description 2
- 206010033668 Panic disorder without agoraphobia Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 208000012202 Pervasive developmental disease Diseases 0.000 claims description 2
- 208000004983 Phantom Limb Diseases 0.000 claims description 2
- 206010056238 Phantom pain Diseases 0.000 claims description 2
- 206010034912 Phobia Diseases 0.000 claims description 2
- 206010070606 Post stroke depression Diseases 0.000 claims description 2
- 208000008348 Post-Concussion Syndrome Diseases 0.000 claims description 2
- 208000004550 Postoperative Pain Diseases 0.000 claims description 2
- 206010036618 Premenstrual syndrome Diseases 0.000 claims description 2
- 206010052276 Pseudodementia Diseases 0.000 claims description 2
- 208000005793 Restless legs syndrome Diseases 0.000 claims description 2
- 208000006289 Rett Syndrome Diseases 0.000 claims description 2
- 208000036353 Rett disease Diseases 0.000 claims description 2
- 206010039966 Senile dementia Diseases 0.000 claims description 2
- 201000001880 Sexual dysfunction Diseases 0.000 claims description 2
- 206010066218 Stress Urinary Incontinence Diseases 0.000 claims description 2
- 208000006011 Stroke Diseases 0.000 claims description 2
- 208000009205 Tinnitus Diseases 0.000 claims description 2
- 208000000323 Tourette Syndrome Diseases 0.000 claims description 2
- 208000016620 Tourette disease Diseases 0.000 claims description 2
- 208000031674 Traumatic Acute Stress disease Diseases 0.000 claims description 2
- 208000000921 Urge Urinary Incontinence Diseases 0.000 claims description 2
- 206010048010 Withdrawal syndrome Diseases 0.000 claims description 2
- 208000026345 acute stress disease Diseases 0.000 claims description 2
- 230000032683 aging Effects 0.000 claims description 2
- 208000022531 anorexia Diseases 0.000 claims description 2
- 230000036506 anxiety Effects 0.000 claims description 2
- 230000036528 appetite Effects 0.000 claims description 2
- 235000019789 appetite Nutrition 0.000 claims description 2
- 208000025748 atypical depressive disease Diseases 0.000 claims description 2
- 208000029560 autism spectrum disease Diseases 0.000 claims description 2
- 208000028683 bipolar I disease Diseases 0.000 claims description 2
- 208000022257 bipolar II disease Diseases 0.000 claims description 2
- 208000022266 body dysmorphic disease Diseases 0.000 claims description 2
- 206010008118 cerebral infarction Diseases 0.000 claims description 2
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 2
- 208000024825 childhood disintegrative disease Diseases 0.000 claims description 2
- 230000037326 chronic stress Effects 0.000 claims description 2
- 208000014826 cranial nerve neuropathy Diseases 0.000 claims description 2
- 206010061428 decreased appetite Diseases 0.000 claims description 2
- 210000001097 facial muscle Anatomy 0.000 claims description 2
- 208000029364 generalized anxiety disease Diseases 0.000 claims description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 2
- 206010023461 kleptomania Diseases 0.000 claims description 2
- 201000003723 learning disability Diseases 0.000 claims description 2
- 230000000938 luteal effect Effects 0.000 claims description 2
- 208000024714 major depressive disease Diseases 0.000 claims description 2
- SCQQIPXRTTWRBK-UHFFFAOYSA-N methyl 3-[5-[(4-benzylpiperidin-1-yl)methyl]-1H-1,2,4-triazol-3-yl]-1H-indole-7-carboxylate Chemical compound COC(C(C=CC=C12)=C1NC=C2C1=NN=C(CN2CCC(CC3=CC=CC=C3)CC2)N1)=O SCQQIPXRTTWRBK-UHFFFAOYSA-N 0.000 claims description 2
- QQYBJYCNCAACSO-UHFFFAOYSA-N methyl 3-[5-[[4-[(3,4-dichlorophenyl)methyl]piperidin-1-yl]methyl]-1H-1,2,4-triazol-3-yl]-1H-indole-7-carboxylate Chemical compound COC(C(C=CC=C12)=C1NC=C2C1=NN=C(CN2CCC(CC(C=C3)=CC(Cl)=C3Cl)CC2)N1)=O QQYBJYCNCAACSO-UHFFFAOYSA-N 0.000 claims description 2
- 206010027599 migraine Diseases 0.000 claims description 2
- 208000013465 muscle pain Diseases 0.000 claims description 2
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims description 2
- 201000003631 narcolepsy Diseases 0.000 claims description 2
- 230000000422 nocturnal effect Effects 0.000 claims description 2
- 235000020824 obesity Nutrition 0.000 claims description 2
- 230000000737 periodic effect Effects 0.000 claims description 2
- 208000023515 periodic limb movement disease Diseases 0.000 claims description 2
- 231100000872 sexual dysfunction Toxicity 0.000 claims description 2
- 208000020685 sleep-wake disease Diseases 0.000 claims description 2
- 201000001716 specific phobia Diseases 0.000 claims description 2
- 208000023516 stroke disease Diseases 0.000 claims description 2
- 125000001424 substituent group Chemical group 0.000 claims description 2
- 210000002820 sympathetic nervous system Anatomy 0.000 claims description 2
- 208000016686 tic disease Diseases 0.000 claims description 2
- 231100000886 tinnitus Toxicity 0.000 claims description 2
- 208000004371 toothache Diseases 0.000 claims description 2
- 208000002271 trichotillomania Diseases 0.000 claims description 2
- 206010046494 urge incontinence Diseases 0.000 claims description 2
- 208000026139 Memory disease Diseases 0.000 claims 2
- 201000009032 substance abuse Diseases 0.000 claims 2
- 231100000736 substance abuse Toxicity 0.000 claims 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 2
- 206010012335 Dependence Diseases 0.000 claims 1
- 208000005171 Dysmenorrhea Diseases 0.000 claims 1
- 206010013935 Dysmenorrhoea Diseases 0.000 claims 1
- 208000020358 Learning disease Diseases 0.000 claims 1
- 241000208125 Nicotiana Species 0.000 claims 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 claims 1
- 206010057852 Nicotine dependence Diseases 0.000 claims 1
- 208000011962 Substance-induced mood disease Diseases 0.000 claims 1
- 231100000395 Substance-induced mood disorder Toxicity 0.000 claims 1
- 208000025569 Tobacco Use disease Diseases 0.000 claims 1
- 235000005607 chanvre indien Nutrition 0.000 claims 1
- 244000261228 chanvre indien Species 0.000 claims 1
- 201000006145 cocaine dependence Diseases 0.000 claims 1
- 230000019771 cognition Effects 0.000 claims 1
- 230000006984 memory degeneration Effects 0.000 claims 1
- 208000023060 memory loss Diseases 0.000 claims 1
- 230000002085 persistent effect Effects 0.000 claims 1
- 229920003216 poly(methylphenylsiloxane) Polymers 0.000 claims 1
- 208000022170 stress incontinence Diseases 0.000 claims 1
- 206010044652 trigeminal neuralgia Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 abstract description 15
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 146
- 238000006243 chemical reaction Methods 0.000 description 103
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 86
- 239000011541 reaction mixture Substances 0.000 description 66
- 239000002904 solvent Substances 0.000 description 61
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 59
- 239000012044 organic layer Substances 0.000 description 52
- 239000012267 brine Substances 0.000 description 48
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 48
- 238000003820 Medium-pressure liquid chromatography Methods 0.000 description 46
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 43
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 39
- 239000002858 neurotransmitter agent Substances 0.000 description 35
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 31
- 238000002360 preparation method Methods 0.000 description 28
- 239000007832 Na2SO4 Substances 0.000 description 27
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 27
- 239000011734 sodium Substances 0.000 description 27
- 229910052938 sodium sulfate Inorganic materials 0.000 description 27
- 235000011152 sodium sulphate Nutrition 0.000 description 27
- 239000000243 solution Substances 0.000 description 27
- 238000000034 method Methods 0.000 description 25
- 210000002569 neuron Anatomy 0.000 description 22
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 22
- 239000012299 nitrogen atmosphere Substances 0.000 description 18
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 16
- 229910052808 lithium carbonate Inorganic materials 0.000 description 16
- 239000003054 catalyst Substances 0.000 description 15
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 15
- XSSIHNQIKLVVAJ-UHFFFAOYSA-N (3-bromo-1h-1,2,4-triazol-5-yl)methanol Chemical compound OCC1=NC(Br)=NN1 XSSIHNQIKLVVAJ-UHFFFAOYSA-N 0.000 description 14
- JHUUPUMBZGWODW-UHFFFAOYSA-N 3,6-dihydro-1,2-dioxine Chemical compound C1OOCC=C1 JHUUPUMBZGWODW-UHFFFAOYSA-N 0.000 description 13
- ABGXADJDTPFFSZ-UHFFFAOYSA-N 4-benzylpiperidine Chemical compound C=1C=CC=CC=1CC1CCNCC1 ABGXADJDTPFFSZ-UHFFFAOYSA-N 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- 239000007864 aqueous solution Substances 0.000 description 12
- 239000000546 pharmaceutical excipient Substances 0.000 description 12
- XXXWULPGHIPIEI-UHFFFAOYSA-N 4-benzyl-1-[(3-bromo-1H-1,2,4-triazol-5-yl)methyl]piperidine Chemical compound BrC1=NN=C(CN2CCC(CC3=CC=CC=C3)CC2)N1 XXXWULPGHIPIEI-UHFFFAOYSA-N 0.000 description 10
- 238000002953 preparative HPLC Methods 0.000 description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- RPGWZZNNEUHDAQ-UHFFFAOYSA-N phenylphosphine Chemical compound PC1=CC=CC=C1 RPGWZZNNEUHDAQ-UHFFFAOYSA-N 0.000 description 9
- 108020003175 receptors Proteins 0.000 description 9
- 102000005962 receptors Human genes 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 8
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 210000000225 synapse Anatomy 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 239000003085 diluting agent Substances 0.000 description 7
- 239000000839 emulsion Substances 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 239000000080 wetting agent Substances 0.000 description 7
- JROWTKYJKHIRGD-UHFFFAOYSA-N 4-[(3,4-dichlorophenyl)methyl]piperidine Chemical compound C1=C(Cl)C(Cl)=CC=C1CC1CCNCC1 JROWTKYJKHIRGD-UHFFFAOYSA-N 0.000 description 6
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 230000006399 behavior Effects 0.000 description 6
- 230000003197 catalytic effect Effects 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000012457 nonaqueous media Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
- 241000209094 Oryza Species 0.000 description 5
- 235000007164 Oryza sativa Nutrition 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- TZHYEXHDCFQZGG-UHFFFAOYSA-N [5-fluoro-1-[(2-methylpropan-2-yl)oxycarbonyl]indol-2-yl]boronic acid Chemical compound FC1=CC=C2N(C(=O)OC(C)(C)C)C(B(O)O)=CC2=C1 TZHYEXHDCFQZGG-UHFFFAOYSA-N 0.000 description 5
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000007911 parenteral administration Methods 0.000 description 5
- 230000001242 postsynaptic effect Effects 0.000 description 5
- 230000003518 presynaptic effect Effects 0.000 description 5
- 235000009566 rice Nutrition 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 5
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- QMXPLRLXVBJVNB-UHFFFAOYSA-N 4-[(3,4-dichlorophenyl)methyl]piperidine;hydrochloride Chemical class Cl.C1=C(Cl)C(Cl)=CC=C1CC1CCNCC1 QMXPLRLXVBJVNB-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- SAAIFDYTSDLURM-UHFFFAOYSA-N [5,6-dimethoxy-1-[(2-methylpropan-2-yl)oxycarbonyl]indol-2-yl]boronic acid Chemical compound CC(C)(C)OC(N(C(B(O)O)=CC1=C2)C1=CC(OC)=C2OC)=O SAAIFDYTSDLURM-UHFFFAOYSA-N 0.000 description 4
- 235000011054 acetic acid Nutrition 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 238000004891 communication Methods 0.000 description 4
- 239000007884 disintegrant Substances 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 235000003599 food sweetener Nutrition 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 150000004677 hydrates Chemical class 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 4
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium;hydroxide;hydrate Chemical compound [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 description 4
- 235000017550 sodium carbonate Nutrition 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 239000003765 sweetening agent Substances 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- IRZPWZYCUJFBJB-UHFFFAOYSA-N tert-butyl 5-methoxy-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indole-1-carboxylate Chemical compound C12=CC(OC)=CC=C2N(C(=O)OC(C)(C)C)C=C1B1OC(C)(C)C(C)(C)O1 IRZPWZYCUJFBJB-UHFFFAOYSA-N 0.000 description 4
- HOPDTPGXBZCBNP-UHFFFAOYSA-N 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=C(C#N)C=C1 HOPDTPGXBZCBNP-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 108010078791 Carrier Proteins Proteins 0.000 description 3
- 206010013654 Drug abuse Diseases 0.000 description 3
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 3
- 239000004606 Fillers/Extenders Substances 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 3
- 102000005665 Neurotransmitter Transport Proteins Human genes 0.000 description 3
- 108010084810 Neurotransmitter Transport Proteins Proteins 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000007900 aqueous suspension Substances 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 150000003943 catecholamines Chemical class 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 3
- 229940093471 ethyl oleate Drugs 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 210000000653 nervous system Anatomy 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 230000001561 neurotransmitter reuptake Effects 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 235000008390 olive oil Nutrition 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 239000006186 oral dosage form Substances 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 239000006201 parenteral dosage form Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 230000000946 synaptic effect Effects 0.000 description 3
- NEVYMHCTIQBRQU-UHFFFAOYSA-N tert-butyl 6-methoxy-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indole-1-carboxylate Chemical compound C=1N(C(=O)OC(C)(C)C)C2=CC(OC)=CC=C2C=1B1OC(C)(C)C(C)(C)O1 NEVYMHCTIQBRQU-UHFFFAOYSA-N 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 2
- DZLFRQHFFVRYEE-UHFFFAOYSA-N 1h-indole-2-carbohydrazide Chemical compound C1=CC=C2NC(C(=O)NN)=CC2=C1 DZLFRQHFFVRYEE-UHFFFAOYSA-N 0.000 description 2
- IAQBURSQTCOSBP-UHFFFAOYSA-N 2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1h-indole Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC2=CC=CC=C2N1 IAQBURSQTCOSBP-UHFFFAOYSA-N 0.000 description 2
- PFCHEBZDXQTGDM-UHFFFAOYSA-N 2-[5-[(4-benzylpiperidin-1-yl)methyl]-1H-1,2,4-triazol-3-yl]-1H-indol-5-amine Chemical compound NC1=CC=C2NC(C3=NN=C(CN4CCC(CC5=CC=CC=C5)CC4)N3)=CC2=C1 PFCHEBZDXQTGDM-UHFFFAOYSA-N 0.000 description 2
- HDHRELSKVISGNG-UHFFFAOYSA-N 6-butoxy-1H-indole-2-carbonyl chloride Chemical compound CCCCOC1=CC=C(C=C(C(Cl)=O)N2)C2=C1 HDHRELSKVISGNG-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- STDYUBJSGXQPPV-UHFFFAOYSA-N CCCCOC1=CC=C(C=C(C(N)=S)N2)C2=C1 Chemical compound CCCCOC1=CC=C(C=C(C(N)=S)N2)C2=C1 STDYUBJSGXQPPV-UHFFFAOYSA-N 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 102000006441 Dopamine Plasma Membrane Transport Proteins Human genes 0.000 description 2
- 108010044266 Dopamine Plasma Membrane Transport Proteins Proteins 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- YNQLUTRBYVCPMQ-UHFFFAOYSA-N Ethylbenzene Chemical compound CCC1=CC=CC=C1 YNQLUTRBYVCPMQ-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 229910002666 PdCl2 Inorganic materials 0.000 description 2
- 102000019208 Serotonin Plasma Membrane Transport Proteins Human genes 0.000 description 2
- 108010012996 Serotonin Plasma Membrane Transport Proteins Proteins 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 206010043903 Tobacco abuse Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 230000001430 anti-depressive effect Effects 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- QCYLIQBVLZBPNK-UHFFFAOYSA-N asiaticoside A Natural products O1C(C(=O)C(C)C)=CC(C)C(C2(C(OC(C)=O)CC34C5)C)C1CC2(C)C3CCC(C1(C)C)C45CCC1OC1OCC(O)C(O)C1O QCYLIQBVLZBPNK-UHFFFAOYSA-N 0.000 description 2
- 210000003050 axon Anatomy 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 210000001787 dendrite Anatomy 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- XUPQGPHSQHXQQJ-UHFFFAOYSA-N ethyl 2-(4-benzylpiperidin-1-yl)acetate Chemical compound C1CN(CC(=O)OCC)CCC1CC1=CC=CC=C1 XUPQGPHSQHXQQJ-UHFFFAOYSA-N 0.000 description 2
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 2
- 230000002964 excitative effect Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- JXDYKVIHCLTXOP-UHFFFAOYSA-N isatin Chemical compound C1=CC=C2C(=O)C(=O)NC2=C1 JXDYKVIHCLTXOP-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 230000013016 learning Effects 0.000 description 2
- KQNQTJBSEWXXIW-UHFFFAOYSA-M lithium 2-(4-benzylpiperidin-1-yl)acetate Chemical compound [O-]C(CN1CCC(CC2=CC=CC=C2)CC1)=O.[Li+] KQNQTJBSEWXXIW-UHFFFAOYSA-M 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 230000008450 motivation Effects 0.000 description 2
- 239000003901 neurotransmitter uptake inhibitor Substances 0.000 description 2
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 2
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000000697 serotonin reuptake Effects 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 210000002504 synaptic vesicle Anatomy 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- FMNXFKVTZJWOAD-UHFFFAOYSA-N tert-butyl 1h-indole-2-carboxylate Chemical compound C1=CC=C2NC(C(=O)OC(C)(C)C)=CC2=C1 FMNXFKVTZJWOAD-UHFFFAOYSA-N 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- ABADUMLIAZCWJD-UHFFFAOYSA-N 1,3-dioxole Chemical compound C1OC=CO1 ABADUMLIAZCWJD-UHFFFAOYSA-N 0.000 description 1
- JWYPHUHIARTOEP-UHFFFAOYSA-N 1-benzyl-4-[(3-bromo-1H-1,2,4-triazol-5-yl)methyl]piperazine Chemical compound BrC1=NN=C(CN2CCN(CC3=CC=CC=C3)CC2)N1 JWYPHUHIARTOEP-UHFFFAOYSA-N 0.000 description 1
- IQXXEPZFOOTTBA-UHFFFAOYSA-N 1-benzylpiperazine Chemical compound C=1C=CC=CC=1CN1CCNCC1 IQXXEPZFOOTTBA-UHFFFAOYSA-N 0.000 description 1
- JFLPYJVQUCPMJT-UHFFFAOYSA-N 1h-indole-2-carbothioamide Chemical compound C1=CC=C2NC(C(=S)N)=CC2=C1 JFLPYJVQUCPMJT-UHFFFAOYSA-N 0.000 description 1
- HCSBTDBGTNZOAB-UHFFFAOYSA-N 2,3-dinitrobenzoic acid Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-N 0.000 description 1
- GDCDFUQZRXYLMG-UHFFFAOYSA-N 2-(4-benzylpiperidin-1-yl)acetohydrazide Chemical compound C1CN(CC(=O)NN)CCC1CC1=CC=CC=C1 GDCDFUQZRXYLMG-UHFFFAOYSA-N 0.000 description 1
- UKPSXUCUXVJOES-UHFFFAOYSA-N 2-[5-[[4-[(3,4-dichlorophenyl)methyl]piperidin-1-yl]methyl]-1H-1,2,4-triazol-3-yl]-5,6-dimethoxy-1H-indole Chemical compound COC(C=C(C=C(C1=NN=C(CN2CCC(CC(C=C3)=CC(Cl)=C3Cl)CC2)N1)N1)C1=C1)=C1OC UKPSXUCUXVJOES-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 description 1
- KAIRZPVWWIMPFT-UHFFFAOYSA-N 3-piperidin-4-yl-1h-indole Chemical compound C1CNCCC1C1=CNC2=CC=CC=C12 KAIRZPVWWIMPFT-UHFFFAOYSA-N 0.000 description 1
- BICZJRAGTCRORZ-UHFFFAOYSA-N 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=C(O)C=C1 BICZJRAGTCRORZ-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 description 1
- PDLIDTOGYMYMLD-UHFFFAOYSA-N 5-bromo-1h-1,2,4-triazole-3-carboxylic acid Chemical compound OC(=O)C1=NN=C(Br)N1 PDLIDTOGYMYMLD-UHFFFAOYSA-N 0.000 description 1
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 208000000103 Anorexia Nervosa Diseases 0.000 description 1
- 206010002941 Apallic syndrome Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- RTLPMJUOBVAFQL-UHFFFAOYSA-N CCCCOC1=CC=C(C=C(C(N)=O)N2)C2=C1 Chemical compound CCCCOC1=CC=C(C=C(C(N)=O)N2)C2=C1 RTLPMJUOBVAFQL-UHFFFAOYSA-N 0.000 description 1
- DIKMLJKWBLRAQC-UHFFFAOYSA-N CCCCOC1=CC=C(C=C(C(NC(C)(C)C)=O)N2)C2=C1 Chemical compound CCCCOC1=CC=C(C=C(C(NC(C)(C)C)=O)N2)C2=C1 DIKMLJKWBLRAQC-UHFFFAOYSA-N 0.000 description 1
- KYRXQZFYFXRJON-UHFFFAOYSA-N CCCCOC1=CC=C(C=C(C(SC)=N)N2)C2=C1 Chemical compound CCCCOC1=CC=C(C=C(C(SC)=N)N2)C2=C1 KYRXQZFYFXRJON-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 206010061619 Deformity Diseases 0.000 description 1
- 206010054089 Depressive symptom Diseases 0.000 description 1
- 208000012239 Developmental disease Diseases 0.000 description 1
- 102000015554 Dopamine receptor Human genes 0.000 description 1
- 108050004812 Dopamine receptor Proteins 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 208000030990 Impulse-control disease Diseases 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- WYQVAPGDARQUBT-FGWHUCSPSA-N Madecassol Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)OC[C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)[C@]12CC[C@H]([C@@H]([C@H]1C=1[C@@]([C@@]3(CC[C@H]4[C@](C)(CO)[C@@H](O)[C@H](O)C[C@]4(C)[C@H]3CC=1)C)(C)CC2)C)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O WYQVAPGDARQUBT-FGWHUCSPSA-N 0.000 description 1
- BNMGUJRJUUDLHW-HCZMHFOYSA-N Madecassoside Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)OC[C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)[C@]12CC[C@H]([C@@H]([C@H]1C=1[C@@]([C@@]3(C[C@@H](O)[C@H]4[C@](C)(CO)[C@@H](O)[C@H](O)C[C@]4(C)[C@H]3CC=1)C)(C)CC2)C)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O BNMGUJRJUUDLHW-HCZMHFOYSA-N 0.000 description 1
- BNMGUJRJUUDLHW-HLUHVYOBSA-N Madecassoside Natural products C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5[C@H](O)C[C@@]34C)[C@@H]2[C@H]1C)C(=O)O[C@@H]6O[C@H](CO[C@@H]7O[C@H](CO)[C@@H](O[C@@H]8O[C@H](C)[C@H](O)[C@@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@@H](O)[C@H](O)[C@H]6O BNMGUJRJUUDLHW-HLUHVYOBSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000017657 Menopausal disease Diseases 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-N Nitrous acid Chemical compound ON=O IOVCWXUNBOPUCH-UHFFFAOYSA-N 0.000 description 1
- 102000008092 Norepinephrine Plasma Membrane Transport Proteins Human genes 0.000 description 1
- 108010049586 Norepinephrine Plasma Membrane Transport Proteins Proteins 0.000 description 1
- KTQAOUSGYXIHPW-UHFFFAOYSA-N O=C(C(N1)=NN=C1Br)N1CCC(CC2=CC=CC=C2)CC1 Chemical compound O=C(C(N1)=NN=C1Br)N1CCC(CC2=CC=CC=C2)CC1 KTQAOUSGYXIHPW-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229910019213 POCl3 Inorganic materials 0.000 description 1
- 208000027030 Premenstrual dysphoric disease Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
- 229940121991 Serotonin and norepinephrine reuptake inhibitor Drugs 0.000 description 1
- 102100028874 Sodium-dependent serotonin transporter Human genes 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical class OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 101710164184 Synaptic vesicular amine transporter Proteins 0.000 description 1
- 102100034333 Synaptic vesicular amine transporter Human genes 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010044688 Trisomy 21 Diseases 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- ZZXDRXVIRVJQBT-UHFFFAOYSA-M Xylenesulfonate Chemical compound CC1=CC=CC(S([O-])(=O)=O)=C1C ZZXDRXVIRVJQBT-UHFFFAOYSA-M 0.000 description 1
- SCZOPXMWIHYWGN-UHFFFAOYSA-N [1-[(2-methylpropan-2-yl)oxycarbonyl]-5-[(2-methylpropan-2-yl)oxycarbonylamino]indol-2-yl]boronic acid Chemical compound CC(C)(C)OC(=O)NC1=CC=C2N(C(=O)OC(C)(C)C)C(B(O)O)=CC2=C1 SCZOPXMWIHYWGN-UHFFFAOYSA-N 0.000 description 1
- AGKMIDIDFCVRPB-UHFFFAOYSA-N [1-[(2-methylpropan-2-yl)oxycarbonyl]-5-[(2-methylpropan-2-yl)oxycarbonylamino]indol-3-yl]boronic acid Chemical compound CC(C)(C)OC(NC(C=C1C(B(O)O)=C2)=CC=C1N2C(OC(C)(C)C)=O)=O AGKMIDIDFCVRPB-UHFFFAOYSA-N 0.000 description 1
- WDVLEQPKPJEFQX-UHFFFAOYSA-N [3-(1H-indol-2-yl)-1H-1,2,4-triazol-5-yl]methanol Chemical compound OCC1=NN=C(C2=CC3=CC=CC=C3N2)N1 WDVLEQPKPJEFQX-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 159000000032 aromatic acids Chemical class 0.000 description 1
- 230000037007 arousal Effects 0.000 description 1
- WYQVAPGDARQUBT-XCWYDTOWSA-N asiaticoside Natural products O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@H](O)[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](CO)O2)O1)[C@@]12[C@@H]([C@@H](C)[C@H](C)CC1)C=1[C@](C)([C@@]3(C)[C@@H]([C@@]4(C)[C@H]([C@@](CO)(C)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2 WYQVAPGDARQUBT-XCWYDTOWSA-N 0.000 description 1
- 229940022757 asiaticoside Drugs 0.000 description 1
- 230000003935 attention Effects 0.000 description 1
- 210000003403 autonomic nervous system Anatomy 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- 150000001539 azetidines Chemical class 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 201000004559 cerebral degeneration Diseases 0.000 description 1
- JOYKCMAPFCSKNO-UHFFFAOYSA-N chloro benzenesulfonate Chemical compound ClOS(=O)(=O)C1=CC=CC=C1 JOYKCMAPFCSKNO-UHFFFAOYSA-N 0.000 description 1
- KVSASDOGYIBWTA-UHFFFAOYSA-N chloro benzoate Chemical compound ClOC(=O)C1=CC=CC=C1 KVSASDOGYIBWTA-UHFFFAOYSA-N 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 201000001272 cocaine abuse Diseases 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical class C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-M decanoate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000003413 degradative effect Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 208000018459 dissociative disease Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000002825 dopamine reuptake Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 208000024732 dysthymic disease Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- JXVSYWSZCLGVLJ-UHFFFAOYSA-N ethyl 2-[4-[(3,4-dichlorophenyl)methyl]piperidin-1-yl]acetate Chemical compound CCOC(CN1CCC(CC(C=C2)=CC(Cl)=C2Cl)CC1)=O JXVSYWSZCLGVLJ-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000028023 exocytosis Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical group C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 210000001652 frontal lobe Anatomy 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000009548 growth disturbance Effects 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- CFHGBZLNZZVTAY-UHFFFAOYSA-N lawesson's reagent Chemical compound C1=CC(OC)=CC=C1P1(=S)SP(=S)(C=2C=CC(OC)=CC=2)S1 CFHGBZLNZZVTAY-UHFFFAOYSA-N 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 229940090813 madecassoside Drugs 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical class [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 125000005341 metaphosphate group Chemical group 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- MMSODGJNFCCKAZ-UHFFFAOYSA-N methyl 2-amino-4-bromobenzoate Chemical compound COC(=O)C1=CC=C(Br)C=C1N MMSODGJNFCCKAZ-UHFFFAOYSA-N 0.000 description 1
- IZYBEMGNIUSSAX-UHFFFAOYSA-N methyl benzenecarboperoxoate Chemical compound COOC(=O)C1=CC=CC=C1 IZYBEMGNIUSSAX-UHFFFAOYSA-N 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 230000000407 monoamine reuptake Effects 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- JUVPIBHZWGVRFL-UHFFFAOYSA-N n,n-dimethyl-2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy]ethanamine Chemical compound C1=CC(OCCN(C)C)=CC=C1B1OC(C)(C)C(C)(C)O1 JUVPIBHZWGVRFL-UHFFFAOYSA-N 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical class C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical class C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000003955 neuronal function Effects 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 208000005026 persistent vegetative state Diseases 0.000 description 1
- DYUMLJSJISTVPV-UHFFFAOYSA-N phenyl propanoate Chemical compound CCC(=O)OC1=CC=CC=C1 DYUMLJSJISTVPV-UHFFFAOYSA-N 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 229950009215 phenylbutanoic acid Drugs 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 235000020004 porter Nutrition 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 210000000063 presynaptic terminal Anatomy 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- UORVCLMRJXCDCP-UHFFFAOYSA-M propynoate Chemical compound [O-]C(=O)C#C UORVCLMRJXCDCP-UHFFFAOYSA-M 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229940116351 sebacate Drugs 0.000 description 1
- CXMXRPHRNRROMY-UHFFFAOYSA-L sebacate(2-) Chemical compound [O-]C(=O)CCCCCCCCC([O-])=O CXMXRPHRNRROMY-UHFFFAOYSA-L 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 1
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 1
- 239000003775 serotonin noradrenalin reuptake inhibitor Substances 0.000 description 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 1
- 208000012201 sexual and gender identity disease Diseases 0.000 description 1
- 208000015891 sexual disease Diseases 0.000 description 1
- 230000006403 short-term memory Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 230000007958 sleep Effects 0.000 description 1
- 208000022925 sleep disturbance Diseases 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- TYFQFVWCELRYAO-UHFFFAOYSA-L suberate(2-) Chemical compound [O-]C(=O)CCCCCCC([O-])=O TYFQFVWCELRYAO-UHFFFAOYSA-L 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical class [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 210000002182 synaptic membrane Anatomy 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 230000028016 temperature homeostasis Effects 0.000 description 1
- KKEYFWRCBNTPAC-UHFFFAOYSA-L terephthalate(2-) Chemical compound [O-]C(=O)C1=CC=C(C([O-])=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-L 0.000 description 1
- 150000003526 tetrahydroisoquinolines Chemical class 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- NHDIQVFFNDKAQU-UHFFFAOYSA-N tripropan-2-yl borate Chemical compound CC(C)OB(OC(C)C)OC(C)C NHDIQVFFNDKAQU-UHFFFAOYSA-N 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 229940071104 xylenesulfonate Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/30—Other Organic compounds
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Psychiatry (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
nは0~5の整数であり;
A1はO、NH、またはSであり;
A2はNまたはCHであり;
L1は直鎖もしくは分岐C1-5アルキレンまたはC(=O)であり;
R1は
Ra1、Ra2、Ra3、Ra4およびRa5は、独立して水素、ハロゲン、ヒドロキシ、アミノ、CN、非置換もしくは1以上のハロゲンで置換されている直鎖もしくは分岐C1-10アルキル、非置換もしくは1以上のハロゲンで置換されている直鎖もしくは分岐C1-10アルコキシ、-C(=O)ORc、-C(=O)N(Rc)2、または-NRcC(=O)Rcであるか、あるいは、Ra2およびRa3は、それらが結合している炭素と一緒になって1つ以上のOを含む5員もしくは6員のヘテロシクロアルケニルを形成し、
Rb1およびRb2は、独立して水素、ハロゲン、CN、非置換もしくは1以上のハロゲンで置換されている直線もしくは分岐C1-10アルキル、非置換もしくは1以上のハロゲンで置換されている直鎖もしくは分岐C1-10アルコキシ、-C(=O)ORc、-C(=O)N(Rc)2、-NRcC(=O)Rc 、またはフェノキシであるか、あるいは、Rb1およびRb2は、それらが結合する炭素と一緒になって1以上のOを含む5員もしくは6員のヘテロシクロアルケニルを形成し、Rb3は水素、ヒドロキシ、C1-3アルキル、またはC1-3アルコキシであり、
Rcは、独立して水素、置換もしくは非置換の直鎖もしくは分岐C1-10アルキルであり、置換アルキルは、ハロゲン、アミノ、メチルアミノおよびジメチルアミノからなる群から選択される1以上の置換基で置換され、
R2は
nは0~5の整数であり;
A1はO、NH、またはSであり;
A2はNまたはCHであり;
L1は直鎖もしくは分岐C1-5アルキレンまたはC(=O)であり;
R1は
Ra1、Ra2、Ra3、Ra4およびRa5は、独立して水素、ハロゲン、ヒドロキシ、アミノ、CN、非置換もしくは1以上のハロゲンで置換されている直鎖もしくは分岐C1-10アルキル、非置換もしくは1以上のハロゲンで置換されている直鎖もしくは分岐C1-10アルコキシ、-C(=O)ORc、-C(=O)N(Rc)2、または-NRcC(=O)Rcであるか、あるいは、Ra2およびRa3は、それらが結合している炭素と一緒になって1つ以上のOを含む5員もしくは6員のヘテロシクロアルケニルを形成し、
Rb1およびRb2は、独立して水素、ハロゲン、CN、非置換もしくは1以上のハロゲンで置換されている直線もしくは分岐C1-10アルキル、非置換もしくは1以上のハロゲンで置換されている直鎖もしくは分岐C1-10アルコキシ、-C(=O)ORc、-C(=O)N(Rc)2、-NRcC(=O)Rc 、またはフェノキシであるか、あるいは、Rb1およびRb2は、それらが結合する炭素と一緒になって1以上のOを含む5員もしくは6員のヘテロシクロアルケニルを形成し、Rb3は水素、ヒドロキシ、C1-3アルキル、またはC1-3アルコキシであり、
Rcは、独立して水素、置換もしくは非置換の直鎖もしくは分岐C1-10アルキルであり、置換アルキルは、ハロゲン、アミノ、メチルアミノおよびジメチルアミノからなる群から選択される1以上の置換基で置換され、
R2は
上記式1において、
R1は
Ra1、Ra2、Ra3、Ra4およびRa5は、独立して水素、ハロゲン、ヒドロキシ、アミノ、CN、非置換もしくは1以上のハロゲンで置換されている直鎖もしくは分岐C1-5アルキル、非置換もしくは1以上のハロゲンで置換されている直鎖もしくは分岐C1-5アルコキシ、-C(=O)ORc、-C(=O)N(Rc)2、または-NRcC(=O)Rcであるか、あるいは、Ra2およびRa3は、それらが結合している炭素と一緒になって1つ以上のOを含む5員もしくは6員のヘテロシクロアルケニルを形成し、
Rb1およびRb2は、独立して水素、ハロゲン、CN、非置換もしくは1以上のハロゲンで置換されている直線もしくは分岐C1-5アルキル、非置換もしくは1以上のハロゲンで置換されている直鎖もしくは分岐C1-5アルコキシ、-C(=O)ORc、-C(=O)N(Rc)2、-NRcC(=O)Rc 、またはフェノキシであるか、あるいは、Rb1およびRb2は、それらが結合する炭素と一緒になって1つもしくは2つのOを含む5員もしくは6員のヘテロシクロアルケニルを形成し、
Rcは、独立して水素、置換もしくは非置換の直鎖もしくは分岐C1-5アルキルであり、置換アルキルは、アミノ、メチルアミノおよびジメチルアミノからなる群から選択される1以上の置換基で置換され、
R2は
nは0~2の整数であり、
A1はO、NH、またはSであり、
A2はNまたはCHであり、
L1はCH2またはC(=O)であり、
R1は
Ra1、Ra2、Ra3、Ra4、およびRa5は、独立して水素、F、Cl、OH、-NH2、CN、メチル、-CF3、メトキシ、-C(=O)OCH3、または-C(=O)OHであり、
Rb1およびRb2は、独立して水素またはメトキシであるか、あるいはRb1およびRb2は、それらが結合している炭素と一緒になって1,3-ジオキソールを形成し、
R2は
<1> 2-(5-((4-ベンジルピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-1H-インドール
<2> 2-(5-((4-ベンジルピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-5-フルオロ-1H-インドール
<3> 2-(5-((4-フェニルピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-1H-インドール
<4> 2-(5-((4-ベンジルピペラジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-1H-インドール
<5> 2-(5-((4-(3,4-ジクロロベンジル)ピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-1H-インドール
<6> 2-(5-((4-(4-メトキシベンジル)ピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-1H-インドール
<7> 2-(5-((4-(4-クロロベンジル)ピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-1H-インドール
<8> 2-(5-((4-(3-クロロベンジル)ピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-1H-インドール
<9> 4-ベンジル-1-((5-フェニル-4H-1,2,4-トリアゾル-3-イル)メチル)ピペリジン
<10> 4-ベンジル-1-((5-(4-メトキシフェニル)-4H-1,2,4-トリアゾル-3-イル)メチル)ピペリジン
<11> (4-ベンジルピペリジン-1-イル)(5-(4-メトキシフェニル)-4H-1,2,4-トリアゾル-3-イル)メタノン
<12> 2-(5-((4-ベンジルピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-5,6-ジメトキシ-1H-インドール
<13> 2-(5-((4-ベンジルピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-5-メトキシ-1H-インドール
<14> 2-(5-((4-ベンジルピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-5-クロロ-1H-インドール
<15> 2-(5-((4-ベンジルピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-5-メチル-1H-インドール
<16> 2-(5-((4-ベンジルピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-6-フルオロ-1H-インドール
<17> 2-(5-((4-ベンジルピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-1H-インドル-5-カルボニトリル
<18> 2-(5-((4-ベンジルピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-6-メトキシ-1H-インドール
<19> 2-(5-((4-ベンジルピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-7-メトキシ-1H-インドール
<20> メチル2-(5-((4-ベンジルピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-1H-インドル-5-カルボキシレート
<21> 4-ベンジル-1-((5-(ナフタレン-2-イル)-4H-1,2,4-トリアゾル-3-イル)メチル)ピペリジン
<22> 3-(5-((4-ベンジルピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-1H-インドール
<23> 2-(5-((4-ベンジルピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-5-(トリフルオロメチル)-1H-インドール
<24> 2-(5-((4-ベンジルピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-4-クロロ-1H-インドール
<25> 1-((5-(ベンゾフラン-2-イル)-4H-1,2,4-トリアゾル-3-イル)メチル)-4-ベンジルピペリジン
<26> 1-((5-(ベンゾ[b]チオフェン-2-イル)-4H-1,2,4-トリアゾル-3-イル)メチル)-4-ベンジルピペリジン
<27> 1-((5-(ベンゾ[d][1,3]ジオキソル-5-イル)-4H-1,2,4-トリアゾル-3-イル)メチル)-4-ベンジルピペリジン
<28> 2-(5-((4-ベンジルピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-1H-インドル-5-カルボン酸
<29> 2-(5-((4-(3,4-ジクロロベンジル)ピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-5-フルオロ-1H-インドール
<30> 2-(5-((4-(3,4-ジクロロベンジル)ピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-5-メチル-1H-インドール
<31> 2-(5-((4-(3,4-ジクロロベンジル)ピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-5,6-ジメトキシ-1H-インドール
<32> 2-(5-((4-(1H-インドル-3-イル)ピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-5-フルオロ-1H-インドール
<33> 2-((4-ベンジルピペリジン-1-イル)メチル)-5-(1H-インドル-2-イル)-1,3,4-オキサジアゾール
<34> 2-((4-(3,4-ジクロロベンジル)ピペリジン-1-イル)メチル)-5-(1H-インドル-2-イル)-1,3,4-オキサジアゾール
<35> 2-(5-((4-ベンジルピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-1H-インドル-5,6-ジオール
<36> 3-(5-((4-ベンジルピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-5-メトキシ-1H-インドール
<37> 3-(5-((4-ベンジルピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-7-メトキシ-1H-インドール
<38> 3-(5-((4-ベンジルピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-6-メチル-1H-インドール
<39> 3-(5-((4-ベンジルピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-5-メチル-1H-インドール
<40> 3-(5-((4-ベンジルピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-7-クロロ-1H-インドール
<41> 3-(5-((4-ベンジルピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-5-クロロ-1H-インドール
<42> メチル3-(5-((4-ベンジルピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-1H-インドル-7-カルボキシレート
<43> 3-(5-((4-ベンジルピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-1H-インドル-5-アミン
<44> 3-(5-((4-(3,4-ジクロロベンジル)ピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-5-メトキシ-1H-インドール
<45> 3-(5-((4-(3,4-ジクロロベンジル)ピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-7-メトキシ-1H-インドール
<46> 4-(5-((4-ベンジルピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)ベンゾニトリル
<47> 4-ベンジル-1-((5-(4-フルオロフェニル)-4H-1,2,4-トリアゾル-3-イル)メチル)ピペリジン
<48> 4-ベンジル-1-((5-(3,4-ジメトキシフェニル)-4H-1,2,4-トリアゾル-3-イル)メチル)ピペリジン
<49> 4-ベンジル-1-((5-(4-(トリフルオロメトキシ)フェニル)-4H-1,2,4-トリアゾル-3-イル)メチル)ピペリジン
<50> 4-ベンジル-1-((5-(4-(トリフルオロメチル)フェニル)-4H-1,2,4-トリアゾル-3-イル)メチル)ピペリジン
<51> N-(4-(5-((4-ベンジルピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)フェニル)アセタミド
<52> 6-(5-((4-ベンジルピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)ナフタレン-2-オール
<53> 4-ベンジル-1-((5-(4-フェノキシフェニル)-4H-1,2,4-トリアゾル-3-イル)メチル)ピペリジン
<54> 4-ベンジル-1-((5-(3-(トリフルオロメトキシ)フェニル)-4H-1,2,4-トリアゾル-3-イル)メチル)ピペリジン
<55> 4-ベンジル-1-((5-(3-(トリフルオロメチル)フェニル)-4H-1,2,4-トリアゾル-3-イル)メチル)ピペリジン
<56> 3-(5-((4-ベンジルピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-6-メトキシ-1H-インドール
<57> 2-(5-((4-ベンジルピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-1H-インドル-5-カルボキサミド
<58> 4-(5-((4-ベンジルピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-N-(2-(ジメチルアミノ)エチル)ベンゾアミド
<59> 3-(5-((4-(3,4-ジクロロベンジル)ピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-6-メトキシ-1H-インドール
<60> メチル3-(5-((4-(3,4-ジクロロベンジル)ピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-1H-インドル-7-カルボキシレート
<61> 4-(3,4-ジクロロベンジル)-1-((5-(4-(トリフルオロメトキシ)フェニル)-4H-1,2,4-トリアゾル-3-イル)メチル)ピペリジン
<62> 4-(3,4-ジクロロベンジル)-1-((5-(4-(トリフルオロメチル)フェニル)-4H-1,2,4-トリアゾル-3-イル)メチル)ピペリジン
<63> メチル2-アミノ-4-(5-((4-ベンジルピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)ベンゾエート
<64> 2-(5-((4-ベンジルピペラジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-5-フルオロ-1H-インドール
<65> 2-(5-((4-ベンジルピペラジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-5-クロロ-1H-インドール
<66> N-(2-(5-((4-ベンジルピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-1H-インドル-5-イル)アセタミド
<67> 2-(5-((4-ベンジルピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-1H-インドル-5-オール
<68> (4-ベンジルピペリジン-1-イル)(5-(5-フルオロ-1H-インドル-2-イル)-4H-1,2,4-トリアゾル-3-イル)メタノン
<69> 2-(5-((4-ベンジルピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-6-ブトキシ-1H-インドール
<70> 2-(5-((4-ベンジルピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-3-メチル-1H-インドール
<71> 2-(5-((4-ベンジルピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-4,6-ジクロロ-1H-インドール
<72> 2-(5-((4-ベンジルピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-5,6-ジクロロ-1H-インドール
<73> 6-(5-((4-ベンジルピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-5H-[1,3]ジオキソロ[4,5-f]インドール
<74> 7-(5-((4-ベンジルピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-2,3-ジヒドロ-6H-[1,4]ジオキシノ[2,3-f]インドール
<75> 3-(5-((4-ベンジルピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-6-フルオロ-1H-インドール、および
<76> 6-(5-((4-ベンジルピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-1H-インドール。
式2で表される化合物と式3で表される化合物とを反応させて式1で表される化合物を調製することを含む調製方法に従って、調製され得る。
R1、R2 A1、A2、L1およびnは、上記式1で定義されたとおりである。
Ra1、Ra2、Ra3、Ra4、およびRa5は、上記式1で定義されるとおりである。
実施例28の2-(5-((4-ベンジルピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾール-3-イル)-1H-インドール-5-カルボン酸(1 eq)をDMFに溶解後、そこに0℃でHBTU(3.5 eq)、塩化アンモニウム(5 eq)およびトリエチルアミン(5 eq)を滴下して添加した。反応物を室温で12時間撹拌した。
ステップ1の(1-(tert-ブトキシカルボニル)-5-イル-フルオロ-1H-インドール-2-イル)ボロン酸の代わりに下記表10に示すRを用いて、実施例11と同様の方法を用い、実施例68の化合物を得た。
本発明による実施例の化合物のセロトニン、ノルエピネフリンおよびドーパミンに対する再取り込み阻害作用を評価するために、以下の実験を行い、その結果を表13に示す。
Claims (11)
- 下記式1で表される化合物
上記の式1において、
nが0~5の整数であり;
A1がO、NH、またはSであり;
A2がNまたはCHであり;
L1が直鎖もしくは分岐C1-5アルキレンまたはC(=O)であり;
R1が
Ra1、Ra2、Ra3、Ra4およびRa5が、独立して水素、ハロゲン、ヒドロキシ、アミノ、CN、非置換もしくは1以上のハロゲンで置換されている直鎖もしくは分岐C1-10アルキル、非置換もしくは1以上のハロゲンで置換されている直鎖もしくは分岐C1-10アルコキシ、-C(=O)ORc、-C(=O)N(Rc)2、または-NRcC(=O)Rcであるか、あるいは、Ra2およびRa3が、それらが結合している炭素と一緒になって1つ以上のOを含む5員もしくは6員のヘテロシクロアルケニルを形成し、
Rb1およびRb2が、独立して水素、ハロゲン、CN、非置換もしくは1以上のハロゲンで置換されている直線もしくは分岐C1-10アルキル、非置換もしくは1以上のハロゲンで置換されている直鎖もしくは分岐C1-10アルコキシ、-C(=O)ORc、-C(=O)N(Rc)2、-NRcC(=O)Rc 、またはフェノキシであるか、あるいは、Rb1およびRb2が、それらが結合する炭素と一緒になって1以上のOを含む5員もしくは6員のヘテロシクロアルケニルを形成し、Rb3が水素、ヒドロキシ、C1-3アルキル、またはC1-3アルコキシであり、
Rcが、独立して水素、置換もしくは非置換の直鎖もしくは分岐C1-10アルキルであり、置換アルキルが、ハロゲン、アミノ、メチルアミノおよびジメチルアミノからなる群から選択される1以上の置換基で置換され、
R2が
化合物、その立体異性体、またはその薬学的に許容される塩。 - nが0~4の整数であり;
A1がO、NH、またはSであり;
A2がNまたはCHであり;
L1が直鎖もしくは分岐C1-3アルキレンまたはC(=O)であり;
R1が
Ra1、Ra2、Ra3、Ra4およびRa5が、独立して水素、ハロゲン、ヒドロキシ、アミノ、CN、非置換もしくは1以上のハロゲンで置換されている直鎖もしくは分岐C1-5アルキル、非置換もしくは1以上のハロゲンで置換されている直鎖もしくは分岐C1-5アルコキシ、-C(=O)ORc、-C(=O)N(Rc)2、または-NRc C(=O)Rcであるか、あるいは、Ra2およびRa3が、それらが結合している炭素と一緒になって1つ以上のOを含む5員もしくは6員のヘテロシクロアルケニルを形成し、
Rb1およびRb2が、独立して水素、ハロゲン、CN、非置換もしくは1以上のハロゲンで置換されている直線もしくは分岐C1-5アルキル、非置換もしくは1以上のハロゲンで置換されている直鎖もしくは分岐C1-5アルコキシ、-C(=O)ORc、-C(=O)N(Rc)2、-NRcC(=O)Rc 、またはフェノキシであるか、あるいは、Rb1およびRb2が、それらが結合する炭素と一緒になって1つもしくは2つのOを含む5員もしくは6員のヘテロシクロアルケニルを形成し、
Rcが、独立して水素、置換もしくは非置換の直鎖もしくは分岐C1-5アルキルであり、置換アルキルは、アミノ、メチルアミノまたはジメチルアミノで置換され、
R2が
- nが0~2の整数であり、
A1がO、NH、またはSであり、
A2がNまたはCHであり、
L1がCH2またはC(=O)であり、
R1が、
Rb1およびRb2が、独立して水素、ハロゲン、OH、-NH2、CN、メチル、-CF3、メトキシ、ブトキシ、-OCF3、-C(=O)OCH3、-C(=O)OH、-C(=O)NH2、-C(=O)NH(CH2)2N(CH3)2、-NHC(=O)CH3、またはフェノキシであるか、あるいは、Rb1およびRb2が、それらが結合している炭素と一緒になって
R2が、
- 式1で表される化合物が、下記の化合物群から選択されるいずれか一つである、請求項1に記載の化合物、その立体異性体、またはその薬学的に許容される塩:
<1> 2-(5-((4-ベンジルピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-1H-インドール
<2> 2-(5-((4-ベンジルピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-5-フルオロ-1H-インドール
<3> 2-(5-((4-フェニルピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-1H-インドール
<4> 2-(5-((4-ベンジルピペラジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-1H-インドール
<5> 2-(5-((4-(3,4-ジクロロベンジル)ピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-1H-インドール
<6> 2-(5-((4-(4-メトキシベンジル)ピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-1H-インドール
<7> 2-(5-((4-(4-クロロベンジル)ピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-1H-インドール
<8> 2-(5-((4-(3-クロロベンジル)ピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-1H-インドール
<9> 4-ベンジル-1-((5-フェニル-4H-1,2,4-トリアゾル-3-イル)メチル)ピペリジン
<10> 4-ベンジル-1-((5-(4-メトキシフェニル)-4H-1,2,4-トリアゾル-3-イル)メチル)ピペリジン
<11> (4-ベンジルピペリジン-1-イル)(5-(4-メトキシフェニル)-4H-1,2,4-トリアゾル-3-イル)メタノン
<12> 2-(5-((4-ベンジルピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-5,6-ジメトキシ-1H-インドール
<13> 2-(5-((4-ベンジルピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-5-メトキシ-1H-インドール
<14> 2-(5-((4-ベンジルピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-5-クロロ-1H-インドール
<15> 2-(5-((4-ベンジルピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-5-メチル-1H-インドール
<16> 2-(5-((4-ベンジルピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-6-フルオロ-1H-インドール
<17> 2-(5-((4-ベンジルピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-1H-インドル-5-カルボニトリル
<18> 2-(5-((4-ベンジルピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-6-メトキシ-1H-インドール
<19> 2-(5-((4-ベンジルピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-7-メトキシ-1H-インドール
<20> メチル2-(5-((4-ベンジルピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-1H-インドル-5-カルボキシレート
<21> 4-ベンジル-1-((5-(ナフタレン-2-イル)-4H-1,2,4-トリアゾル-3-イル)メチル)ピペリジン
<22> 3-(5-((4-ベンジルピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-1H-インドール
<23> 2-(5-((4-ベンジルピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-5-(トリフルオロメチル)-1H-インドール
<24> 2-(5-((4-ベンジルピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-4-クロロ-1H-インドール
<25> 1-((5-(ベンゾフラン-2-イル)-4H-1,2,4-トリアゾル-3-イル)メチル)-4-ベンジルピペリジン
<26> 1-((5-(ベンゾ[b]チオフェン-2-イル)-4H-1,2,4-トリアゾル-3-イル)メチル)-4-ベンジルピペリジン
<27> 1-((5-(ベンゾ[d][1,3]ジオキソル-5-イル)-4H-1,2,4-トリアゾル-3-イル)メチル)-4-ベンジルピペリジン
<28> 2-(5-((4-ベンジルピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-1H-インドル-5-カルボン酸
<29> 2-(5-((4-(3,4-ジクロロベンジル)ピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-5-フルオロ-1H-インドール
<30> 2-(5-((4-(3,4-ジクロロベンジル)ピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-5-メチル-1H-インドール
<31> 2-(5-((4-(3,4-ジクロロベンジル)ピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-5,6-ジメトキシ-1H-インドール
<32> 2-(5-((4-(1H-インドル-3-イル)ピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-5-フルオロ-1H-インドール
<33> 2-((4-ベンジルピペリジン-1-イル)メチル)-5-(1H-インドル-2-イル)-1,3,4-オキサジアゾール
<34> 2-((4-(3,4-ジクロロベンジル)ピペリジン-1-イル)メチル)-5-(1H-インドル-2-イル)-1,3,4-オキサジアゾール
<35> 2-(5-((4-ベンジルピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-1H-インドル-5,6-ジオール
<36> 3-(5-((4-ベンジルピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-5-メトキシ-1H-インドール
<37> 3-(5-((4-ベンジルピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-7-メトキシ-1H-インドール
<38> 3-(5-((4-ベンジルピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-6-メチル-1H-インドール
<39> 3-(5-((4-ベンジルピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-5-メチル-1H-インドール
<40> 3-(5-((4-ベンジルピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-7-クロロ-1H-インドール
<41> 3-(5-((4-ベンジルピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-5-クロロ-1H-インドール
<42> メチル3-(5-((4-ベンジルピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-1H-インドル-7-カルボキシレート
<43> 3-(5-((4-ベンジルピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-1H-インドル-5-アミン
<44> 3-(5-((4-(3,4-ジクロロベンジル)ピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-5-メトキシ-1H-インドール
<45> 3-(5-((4-(3,4-ジクロロベンジル)ピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-7-メトキシ-1H-インドール
<46> 4-(5-((4-ベンジルピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)ベンゾニトリル
<47> 4-ベンジル-1-((5-(4-フルオロフェニル)-4H-1,2,4-トリアゾル-3-イル)メチル)ピペリジン
<48> 4-ベンジル-1-((5-(3,4-ジメトキシフェニル)-4H-1,2,4-トリアゾル-3-イル)メチル)ピペリジン
<49> 4-ベンジル-1-((5-(4-(トリフルオロメトキシ)フェニル)-4H-1,2,4-トリアゾル-3-イル)メチル)ピペリジン
<50> 4-ベンジル-1-((5-(4-(トリフルオロメチル)フェニル)-4H-1,2,4-トリアゾル-3-イル)メチル)ピペリジン
<51> N-(4-(5-((4-ベンジルピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)フェニル)アセタミド
<52> 6-(5-((4-ベンジルピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)ナフタレン-2-オール
<53> 4-ベンジル-1-((5-(4-フェノキシフェニル)-4H-1,2,4-トリアゾル-3-イル)メチル)ピペリジン
<54> 4-ベンジル-1-((5-(3-(トリフルオロメトキシ)フェニル)-4H-1,2,4-トリアゾル-3-イル)メチル)ピペリジン
<55> 4-ベンジル-1-((5-(3-(トリフルオロメチル)フェニル)-4H-1,2,4-トリアゾル-3-イル)メチル)ピペリジン
<56> 3-(5-((4-ベンジルピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-6-メトキシ-1H-インドール
<57> 2-(5-((4-ベンジルピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-1H-インドル-5-カルボキサミド
<58> 4-(5-((4-ベンジルピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-N-(2-(ジメチルアミノ)エチル)ベンゾアミド
<59> 3-(5-((4-(3,4-ジクロロベンジル)ピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-6-メトキシ-1H-インドール
<60> メチル3-(5-((4-(3,4-ジクロロベンジル)ピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-1H-インドル-7-カルボキシレート
<61> 4-(3,4-ジクロロベンジル)-1-((5-(4-(トリフルオロメトキシ)フェニル)-4H-1,2,4-トリアゾル-3-イル)メチル)ピペリジン
<62> 4-(3,4-ジクロロベンジル)-1-((5-(4-(トリフルオロメチル)フェニル)-4H-1,2,4-トリアゾル-3-イル)メチル)ピペリジン
<63> メチル2-アミノ-4-(5-((4-ベンジルピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)ベンゾエート
<64> 2-(5-((4-ベンジルピペラジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-5-フルオロ-1H-インドール
<65> 2-(5-((4-ベンジルピペラジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-5-クロロ-1H-インドール
<66> N-(2-(5-((4-ベンジルピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-1H-インドル-5-イル)アセタミド
<67> 2-(5-((4-ベンジルピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-1H-インドル-5-オール
<68> (4-ベンジルピペリジン-1-イル)(5-(5-フルオロ-1H-インドル-2-イル)-4H-1,2,4-トリアゾル-3-イル)メタノン
<69> 2-(5-((4-ベンジルピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-6-ブトキシ-1H-インドール
<70> 2-(5-((4-ベンジルピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-3-メチル-1H-インドール
<71> 2-(5-((4-ベンジルピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-4,6-ジクロロ-1H-インドール
<72> 2-(5-((4-ベンジルピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-5,6-ジクロロ-1H-インドール
<73> 6-(5-((4-ベンジルピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-5H-[1,3]ジオキソロ[4,5-f]インドール
<74> 7-(5-((4-ベンジルピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-2,3-ジヒドロ-6H-[1,4]ジオキシノ[2,3-f]インドール
<75> 3-(5-((4-ベンジルピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-6-フルオロ-1H-インドール、および
<76> 6-(5-((4-ベンジルピペリジン-1-イル)メチル)-4H-1,2,4-トリアゾル-3-イル)-1H-インドール。 - 請求項1に記載の式1で表される化合物、その立体異性体、またはその薬学的に許容される塩を有効成分として含む、精神障害の予防または治療に使用するための医薬組成物。
- 前記化合物が、セロトニン、ノルエピネフリンおよびドーパミンの再取り込みを阻害する、請求項7に記載の医薬組成物。
- 前記精神障害が、神経性過食症、気分障害、うつ病、非定型うつ病、疼痛に続発するうつ病、大うつ病性障害、ジスティミック障害、双極性障害、双極I型障害、双極II型障害、周期性障害、一般的な医学的状態による気分障害、物質誘発性気分障害、疑似認知症、ガンジャー症候群、強迫性障害、パニック障害、広場恐怖を伴わないパニック障害、広場恐怖を伴うパニック障害、パニック障害の既往がない広場恐怖、パニック発作、記憶欠損、記憶喪失、注意欠陥多動性障害、肥満、不安、全般性不安障害、摂食障害、パーキンソン病、パーキンソン症状、認知症、老化性認知症、老人性認知症、アルツハイマー病、ダウン症、後天性免疫不全症候群認知症合併症、老化による記憶機能障害、特定恐怖症、社会恐怖症、社会不安障害、心的外傷後ストレス障害、急性ストレス障害、慢性ストレス障害、薬物中毒、薬物乱用、薬物乱用傾向、コカイン中毒、ニコチン中毒、タバコ中毒、アルコール中毒、アルコール依存症、病的クレプトマニア、中毒物質離脱による離脱症候群、疼痛、慢性疼痛、炎症性疼痛、神経障害性疼痛、糖尿病性神経障害性疼痛、片頭痛、緊張型頭痛、慢性緊張型頭痛、うつ関連痛、腰痛、癌性疼痛、過敏性腸症候群、術後痛、乳房切除後疼痛症候群(PMPS)、脳卒中後疼痛。薬物性神経障害、糖尿病性神経障害、交感神経系による疼痛、三叉神経痛、歯痛、顔面筋肉痛、幻肢痛、食欲不振、月経前症候群、月経困難症、黄体後期症候群、外傷後症候群、慢性疲労症候群、遷延性植物状態尿失禁、ストレス性尿失禁、切迫性尿失禁、夜間尿失禁、性機能障害、早漏、勃起障害、レストレスレッグス症候群、周期性四肢運動障害、摂食障害、神経性無食欲症、睡眠障害、広汎性発達障害、自閉症、アスペルガー障害、Rett障害、小児性崩壊性障害、学習障害、運動能力障害、緘黙症、トリコチロマニア、ナルコレプシー、脳卒中後うつ病、脳梗塞、脳神経障害、トゥレット症候群、耳鳴り、チック障害、身体醜形障害、反抗性障害、脳卒中後障害、からなる群から選択される一つ以上である、請求項7に記載の医薬組成物。
- 請求項1に記載の式1で表される化合物、その立体異性体またはその薬学的に許容される塩を有効成分として含む、精神障害の予防または治療に使用するための、セロトニン、ノルエピネフリンおよびドーパミンの3重再取り込み阻害薬。
- 請求項1に記載の式1で表される化合物、その立体異性体、またはその薬学的に許容される塩を有効成分として含む、精神障害の予防または改善に使用するための健康機能性食品組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20200065506 | 2020-05-29 | ||
KR10-2020-0065506 | 2020-05-29 | ||
PCT/KR2021/006496 WO2021241982A1 (ko) | 2020-05-29 | 2021-05-25 | N을 하나 이상 포함하는 5원자의 헤테로아릴 유도체 및 이를 유효성분으로 함유하는 정신질환의 예방 또는 치료용 약학적 조성물 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2023528547A true JP2023528547A (ja) | 2023-07-04 |
Family
ID=78744074
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023517643A Pending JP2023528547A (ja) | 2020-05-29 | 2021-05-25 | 少なくとも1つのnを含む5員ヘテロアリール誘導体、ならびにこれを有効成分として含有する精神障害の予防または治療に使用するための医薬組成物 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20230212144A1 (ja) |
EP (1) | EP4159726A4 (ja) |
JP (1) | JP2023528547A (ja) |
KR (1) | KR102397705B1 (ja) |
CN (1) | CN116057053A (ja) |
WO (1) | WO2021241982A1 (ja) |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5633376A (en) * | 1990-12-28 | 1997-05-27 | Neurogen Corporation | Certain aminomethyl phenylimidazole derivatives; and 4-aryl substituted piperazinyl and piperidinylmethyl phenylimidazole derivatives; a new class of dopamine receptor subtype ligands |
US20030018025A1 (en) * | 1995-06-07 | 2003-01-23 | Neurogen Corporation, Corporation Of The State Of Delaware | Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives: new classes of dopamine receptor subtype specific ligands |
DE19728996A1 (de) * | 1997-07-07 | 1999-01-14 | Basf Ag | Triazolverbindungen und deren Verwendung |
US6288230B1 (en) * | 1998-09-29 | 2001-09-11 | Neurogen Corporation | 2-(2, 3-dihydrobenzofuran-5-yl)-4-aminomethylimidazoles: dopamine receptor subtype specific ligands |
ATE387429T1 (de) | 1999-11-03 | 2008-03-15 | Amr Technology Inc | Arly- und heteroaryl-substituierte tetrahydroisoquinoline und ihre verwendung als hemmer der wiederaufnahme von norepinephrin, dopamin und serotonin |
TW200836732A (en) | 2006-12-20 | 2008-09-16 | Neurosearch As | Novel compounds |
KR101183045B1 (ko) | 2007-02-12 | 2012-09-20 | 인두스 바이오텍 프라이빗 리미티드 | 선택적 세로토닌 재흡수 억제를 위한 조성물 및 그 제조 방법 |
EP3296289A3 (en) | 2007-05-31 | 2018-06-20 | Sunovion Pharmaceuticals Inc. | Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors |
US8609696B2 (en) * | 2008-12-18 | 2013-12-17 | Boehringer Ingelheim International Gmbh | Serotonin 5-HT2B receptor inhibitors |
KR101152658B1 (ko) * | 2009-04-30 | 2012-06-18 | 한국과학기술연구원 | 세로토닌 5-ht6 길항 활성 효과를 갖는 피페라진 화합물 함유 조성물 |
JP2012180281A (ja) * | 2009-06-29 | 2012-09-20 | Dainippon Sumitomo Pharma Co Ltd | 新規オキサジアゾール誘導体 |
EP2560643A1 (en) * | 2010-04-20 | 2013-02-27 | Institute for OneWorld Health | Compounds, compositions and methods comprising 1,3,4-oxadiazole derivatives |
KR101273566B1 (ko) | 2011-09-05 | 2013-06-11 | 한국과학기술연구원 | 신규한 아제티딘 유도체 및 이를 함유하는 항우울제 조성물 |
WO2020123847A1 (en) * | 2018-12-12 | 2020-06-18 | Rutgers, The State University Of New Jersey | Organic compounds |
-
2021
- 2021-05-25 CN CN202180058743.2A patent/CN116057053A/zh active Pending
- 2021-05-25 KR KR1020210066920A patent/KR102397705B1/ko active IP Right Grant
- 2021-05-25 US US17/927,973 patent/US20230212144A1/en active Pending
- 2021-05-25 WO PCT/KR2021/006496 patent/WO2021241982A1/ko unknown
- 2021-05-25 JP JP2023517643A patent/JP2023528547A/ja active Pending
- 2021-05-25 EP EP21813774.3A patent/EP4159726A4/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP4159726A1 (en) | 2023-04-05 |
WO2021241982A1 (ko) | 2021-12-02 |
KR20210147923A (ko) | 2021-12-07 |
EP4159726A4 (en) | 2023-11-15 |
KR102397705B1 (ko) | 2022-05-13 |
CN116057053A (zh) | 2023-05-02 |
US20230212144A1 (en) | 2023-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2794593B1 (en) | Spiro aminic compounds as orexin antagonists | |
ES2579830T3 (es) | Derivados de diaminopirimidina y procedimientos para la preparación de los mismos | |
CA2731196A1 (en) | Benzazepine derivatives and their use as hstamine h3 antagonists | |
HRP20030771A2 (en) | N-(2-arylethyl)benzylamines as antagonists of the 5-ht<sub>6</sub> receptor | |
JP2011502148A (ja) | 疼痛の治療用としてのp2x3受容体アンタゴニスト | |
KR20070097405A (ko) | 이소인돌론 화합물 및 대사성 글루타메이트 수용체증강제로서 이들의 용도 | |
AU2003224719A1 (en) | Pyridinoylpiperidines as 5-ht1f agonists | |
TWI583687B (zh) | 2-氧雜-5-氮雜雙環[2.2.1]庚-3-基衍生物 | |
EA016888B1 (ru) | Производные бензимидазола | |
JP2011157358A (ja) | グリシン輸送阻害薬としての二環式[3.1.0]誘導体 | |
NO341965B1 (no) | Benzimidazolmodulatorer av VR1 | |
JP2007529474A (ja) | 高血圧の処置のためのレニン阻害剤としての5−アミノ−4−ヒドロキシ−7−(1h−インドールメチル)−8−メチルノンアミド誘導体 | |
TWI748492B (zh) | 作為組蛋白去乙醯酶6抑制劑之1,3,4-㗁二唑衍生物及含彼之醫藥組合物 | |
CN103052636A (zh) | D2拮抗剂及其合成方法和使用方法 | |
RU2553453C2 (ru) | 4-замещенные-2-феноксифениламиновые модуляторы дельта-опиоидных рецепторов | |
WO2009127944A1 (en) | Ether benzylidene piperidine aryl carboxamide compounds useful as faah inhibitors | |
JP7114594B2 (ja) | 複素環化合物 | |
RU2637938C2 (ru) | Производные триазолкарбоксамида | |
JP2007535548A (ja) | ドーパミンアゴニストとしての3−ピペリジニルイソクロマン−5−オール | |
RU2690154C2 (ru) | Производные морфолин-пиридина | |
ES2414159T3 (es) | Antagonistas de acrilamida piperidilo de CCR2 | |
EP2504316A1 (en) | Heterocylic compounds as antagonists of the orexin receptors | |
CA2882821A1 (en) | Pyrazole carboxamide derivatives and uses thereof as taar modulators | |
JP6831376B2 (ja) | トリアゾール誘導体 | |
JP2023528547A (ja) | 少なくとも1つのnを含む5員ヘテロアリール誘導体、ならびにこれを有効成分として含有する精神障害の予防または治療に使用するための医薬組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230301 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20240215 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240325 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20240605 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20240605 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240624 |